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ABSTRACT

Brain metastasis is a common cause of mortality in cancer patients. Approximately
20-30% of breast cancer patients acquire brain metastasis, yet potential therapeutic
targets remain largely unknown. The type I insulin-like growth factor receptor (IGFIR) is known to play a role in the progression of breast cancer and is currently being
investigated in the clinical setting for various types of cancer. The present study
demonstrates that the IGF-IR signaling axis is constitutively active in brain-seeking
sublines of breast cancer cells, driving an increase in in vitro metastatic properties.
We demonstrate that IGF-IR signaling is activated in an autocrine manner as a
result of IGFBP3 overexpression in brain-seeking cells.

Transient and stable

knockdown of IGF-IR results in a downregulation of IGF-IR downstream signaling
through phospho-AKT, as well as decreased in vitro migration and invasion of MDAMB-231Br brain-seeking cells.

Using an in vivo experimental brain metastasis

model, we show that IGF-IR ablation attenuates the establishment of brain
metastases and prolongs survival. Finally, we demonstrate that the malignancy of
brain-seeking

cells

is

attenuated

by

pharmacological

inhibition

with
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picropodophyllin, an IGF-IR-specific tyrosine kinase inhibitor. Together, our data
suggest that the IGF-IR is an important mediator of brain metastasis and its ablation
delays the onset of brain metastases in our model system.
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INTRODUCTION
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1.1 Metastatic Brain Tumors (MBTs) of Breast Cancer
Brain metastases are the most frequent type of malignant brain tumors, and they
commonly originate from lung, breast, melanoma, renal, and colon cancers
(Barnholtz-Sloan et al., 2004; Eichler et al., 2011; Weil, Palmieri, Bronder, Stark, &
Steeg, 2005). Approximately 10-16% of breast cancer patients develop brain
metastases, and this continues to be a major cause of mortality in women
(Barnholtz-Sloan et al., 2004; Cheng & Hung, 2007; Saunus, Momeny, Simpson,
Lakhani, & Da Silva, 2011; Weil et al., 2005). The mean survival of patients with
brain metastases ranges from 3-18 months, with a one-year survival rate of 20%
(Andrews et al., 2004; Cheng & Hung, 2007; Sperduto et al., 2010). One recent
retrospective study found that the presence of leptomeningeal disease (LMD) or
triple-negative/Her2 status correlated with an even poorer than overall median
survival of 3.1 months (Quigley, Fukui, Chew, Bhatia, & Karlovits, 2012).

A

retrospective study found that survival time is longer in patients who had a single
metastatic lesion at diagnosis that was resected by surgery or gamma knife surgery
(14.9 months), followed by patients who received whole brain radiotherapy alone
(5.4 months), as compared to the patients who received no treatment (2.1 months)
(S. S. Lee et al., 2008). The incidence of brain metastases is thought to be on the
rise as patients are living longer due to the success of current therapies at
controlling systemic disease while increasing the likelihood of circulating tumor cells
to infiltrate the blood brain barrier (Cheng & Hung, 2007; Steeg, Camphausen, &
Smith, 2011). Brain metastases are even more common in patients with Her2	
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positive breast cancer who received treatment with Trastuzumab, which is very
effective at controlling Her2-positive systemic disease but has poor effectiveness in
the brain due to presence of the blood-brain barrier (N. U. Lin & Winer, 2007).
Unfortunately, the increase in the proportion of patients presenting with brain
metastases has not been met with a corresponding increase in available
treatments, and there remains an urgent need for effective therapies to prevent and
treat this condition.

1.2 Organ specificity of breast cancer metastasis
Stephen Paget’s 1889 “seed and soil” hypothesis predicted that cancer cells, or
“seeds” crosstalk with certain organ microenvironments, or “soil”, during the process
of metastasis (Paget, 1989). Another theory of cancer metastasis is the anatomical
or mechanical model, which posits that tumor cells metastasize to the first organ
they encounter in the circulation, as in the case of colon cancer liver metastasis
(Langley & Fidler, 2011). The extent to which each of the models most closely
describes the process of metastasis remains unclear, but the consensus is that both
anatomical and microenvironmental factors are at play. Like several other cancer
types, breast cancer preferentially metastasizes to certain organs, including the
bone, lungs and liver. Figure 1 shows a schematic of a metastasizing breast cancer
cell and the various barriers it must overcome in order to establish successful
metastases. The brain is typically the last organ to acquire metastatic lesions, due
to the initial protection provided by the blood-brain-barrier.
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Molecular mechanisms underlying organ-specificity are continuously being
uncovered, but there is still a long way to go in our understanding.

A major

determinant of breast cancer cells’ ability to colonize in a new niche depends on the
ability of the tumor cells to arrest, adhere to and penetrate the different organ
barriers, and subsequent survival and proliferation of the cells in the metastatic
niche. Figure 1 depicts a metastatic breast cancer cell in the circulation, and the
various layers that must be overcome in order for the cell to invade the bone, lung
and brain (Nguyen, Bos, & Massague, 2009).
In bone metastasis, chemokines such as SDF-1, osteonectin and osteopontin,
among others, are known to promote breast cancer cell homing to the bone
(Langley & Fidler, 2011). Expression level of CXCR4, the SDF-1 receptor in breast
cancer cells was found to predict bone relapse in a recent clinical trial of patients
with breast cancer (Sacanna et al., 2011).

Furthermore, a gene signature

comprising mainly of cell surface and secreted proteins was found to determine the
bone-specific metastasis of 231 breast cancer cells (Kang et al., 2003). Two of the
genes, interleukin-11 and CTGF, corresponded to osteolytic factors that are further
enhanced by the prometastatic cytokine TGF beta, which is commonly secreted in
bone (Buijs, Stayrook, & Guise, 2011).
Brain metastasis is a relatively new field of study, and it has recently come into
focus due to its increasing incidence, limited treatment options and dismal survival
rates.

A 2009 study by Bos. et al. identified several genes that mediate

extravasation

of

breast

cancer

cells

through

the

blood-brain-barrier.
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Cyclooxygenase COX2, HB-EGF (an EGFR ligand) and ST6GALNAC5, a
sialyltransferase collectively accounted for the brain-metastatic properties of breast
cancer cell lines (Bos et al., 2009). Another study by Palmieri et al. found Her2
overexpression increases brain metastasis of 231 breast cancer cells in a mouse
model (Palmieri et al., 2007). In a subsequent study, the same group discovered
that PEDF, a secreted cytokine, is downregulated in brain metastases, and its
restoration inhibits the outgrowth of large brain metastases, while simultaneously
offering neuroprotection to neuronal cells (Fitzgerald et al., 2012). Furthermore, a
recent study by Su et. al. found that TAp63-/- mice can develop mammary
carcinomas that spontaneously metastasize to the lung, liver and brain (Su et al.,
2010). Another study showed that CXCR4 and its ligand SDF-1 alpha promoted
migration the transendothelial migration of breast cancer cells by increasing
permeability of monolayers of brain microvascular endothelial cells (B. C. Lee, Lee,
Avraham, & Avraham, 2004).

Most recently, a study by Okuda et al showed

microRNA-7 is downregulated in brain metastases of breast cancer, resulting in
upregulation of KLF4, which endows metastatic breast cancer cells with stem-like
qualities and brain-specificity (Okuda et al., 2013).
Despite these advances in the study of brain metastasis in breast cancer, there is
much work to be done to complete our understanding of the disease.
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Figure 1
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Figure 1. Potential barriers to metastasis of breast cancer to different sites.
"Breast cancer cells entering the circulation can infiltrate a distant organ if they
carry the necessary functions for extravasation. The fenestrated structure of bone
marrow sinusoid capillaries is more permissive to cancer cell infiltration than the
contiguous structure of lung capillary walls. Brain capillaries are more difficult to
penetrate, owing to the unique nature of the blood-brain-barrier. Infiltration through
these barriers selects for tumor cells that express the necessary extravasation
functions. These functions can be provided by genes for which expression in
primary tumors independently provides a selective growth advantage (such as
vascular remodeling) or by genes for which expression in primary tumors provides
no benefit but is a consequence of tumor microenvironment signals.”
Reprinted with permission from Macmillan Publishers LTD: [Nature Reviews
Cancer] (Nguyen et al., 2009), copyright 2009.
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1.3 Role of the organ microenvironment in metastasis
It is well established that the tumor microenvironment actively participates in the
metastatic process, through the interaction with the Extracellular Matrix (ECM) and
recruitment of a variety of cells including tumor-associated fibroblasts, immune cells
and bone-marrow derived cells (Joyce & Pollard, 2009). A recent study published
by Luga et. al. showed that breast cancer associated fibroblasts secrete exosomes
that activate the Wnt-PCP (planar cell polarity) pathway which induces cancer cell
protrusions and motility, leading to metastasis (Luga et al., 2012).

The tumor

microenvironment, thus, is an important factor in determining whether metastatic
foci will establish successfully.
1.4 EMT and tumor cell plasticity in metastasis
EMT, or epithelial-mesenchymal-transition, is the process by which cells switch their
morphology and biochemical properties from epithelial to mesenchymal type (Kalluri
& Weinberg, 2009). This process involves loss of expression of epithelial markers
such as E-cadherin, adherens junction proteins and catenins, concomitant with a
gain of expression in mesenchymal markers such as vimentin and fibronectin
(Thiery, 2002). EMT allows cancer cells to dissociate from the tumor and acquire
the ability for invasion and metastasis (Kalluri & Weinberg, 2009). However, the
role of EMT in metastasis is considered “controversial”, due to a scarcity of in vivo
evidence of the EMT process. The controversy is fueled by studies that found
metastatic tumors tend to have epithelial-like properties, not mesenchymal
properties as suggested by the EMT theory (Ledford, 2011). However, many argue
that EMT must be a reversible process, termed MET, necessary for metastatic cells
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to survive and proliferate in the target organ. A recent paper by Tsai and
colleagues in the journal Cancer Cell showed that inducible expression of the
transcription factor Twist1 is sufficient to promote the EMT transition in cancer cells,
and shutting off this protein in the target organ where cells have metastasized
results in a reversion of EMT, or MET, and allows cells to proliferate successfully in
the metastatic site (Tsai, Donaher, Murphy, Chau, & Yang, 2012). In addition, Tsai
et al. argue that a “partial EMT” may be sufficient for metastasis in some cases, a
feature that facilitates the MET process in the distant organ and which has been
reported in a recent study of bladder cancer metastasis (Tran et al., 2013).
Furthermore, it has been shown that repression of MET-inducing factors (Ocana et
al., 2012) and a reversal of EMT is a hallmark of successful metastasis (Chaffer et
al., 2006). Interestingly, a partial MET phenotype was reported by Chao et al. in
prostate cancer and breast cancer metastases, including brain metastases,
characterized by re-expression of E-cadherins with mostly conserved expression of
mesenchymal markers (Y. Chao, Wu, Acquafondata, Dhir, & Wells, 2012). The
authors postulated that a partial MET not only facilitates metastasis in the first target
distant site, but also facilitates the subsequent round of EMT that enables
metastasis from metastasis. Taken together, these recent studies point to a
metastasis model whereby tumor cells possess a degree of plasticity that is molded
by the primary tumor and the metastatic site’s stromal microenvironment, rather
than a fixed genetic signature that dictates a sequence of metastatic steps.
However, even with mounting evidence in favor of EMT/MET theory, there is a
different school of thought that advocates for genetic selection, or a kind of
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Darwinian adaptation as the basis for metastasis. This theory posits that metastasis
is the end result of a series of genetic mutations that occur in response to
environmental pressures. Rather than one theory prevailing over the other, it is
likely that both mechanisms are at play in metastasis formation. Scheel et al., for
example, propose that genetic selection is likely responsible for the early stages of
metastasis leading up to the pre-invasive stage, while it is unlikely that genetic
evolution is responsible for all of the biochemical and morphological changes that
allow cells to dissociate from the solid tumor. This is supported by observations that
EMT typically takes place in the outer edges of “epithelial islands” within solid
tumors (Scheel, Onder, Karnoub, & Weinberg, 2007); in other words, EMT happens
primarily in those cells that are in direct contact with the host microenvironment, not
in the entire tumor as would be expected in a genetic adaptation model. Still, other
cases exist that support a clonal selection model in which particular genetic profiles
give rise to metastasis, such as evidenced in medulloblastoma metastases that
have nearly identical genetic profiles to each other, but different from their primary
tumor of origin (Wu et al., 2012). Therefore, it is important to keep in mind both of
these theories when evaluating the role of IGF-IR in brain metastasis of breast
cancer in our model system.
1.5 Blood-Brain Barrier
The blood-brain barrier (BBB) is the layer that separates the brain microvessels’
capillary lumen from the brain parenchyma, and it plays an important role in both
initially blocking tumor cell invasion and protection of the tumor cells once they have
begun the process of invasion (Wilhelm, Molnar, Fazakas, Hasko, & Krizbai, 2013).
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The BBB is composed of endothelial cells, a basal membrane, pericytes and
astrocytes(Cheng & Hung, 2007; Wilhelm et al., 2013). The BBB endothelial cells
are connected by tight junctions and adherens junctions, which are composed of
transmembrane proteins such as occludin, claudins, immunoglobulin-like molecules
also known as junctional adhesion molecules, and others that have not been well
characterized(Cheng & Hung, 2007; Wilhelm et al., 2013).
1.6 Therapies for brain metastatic breast cancer
Therapeutic approaches for the treatment of brain metastasis are limited. In cases
where brain metastases are diffuse, whole-brain radiotherapy (WBRT) is a standard
therapy, but mainly provides a palliative solution, since tumors inevitably become
resistant to radiation and recur (Padovani, Muracciole, & Regis, 2012). One recent
study identified the Hepatocyte growth factor (HGF) – c-Met pathway as
overexpressed in breast cancer lines that were irradiated.

By combination of

radiotherapy and c-Met inhibitors, they were able to harness this resistance
pathway and synergistic effects in a mouse model, which may be a future direction
for this line of treatment (Yang et al., 2013).
Stereotactic radiosurgery (SRS), or gamma-knife radiosurgery, is used in cases with
3 or less metastatic lesions. Survival rates of patients treated by gamma-knife vary
by subtype of the primary tumor, with HR+/Her2+ (luminal Her2) subtypes showing
the longest survival and HR-/Her2- (basal type) with the lowest survival (Vern-Gross
et al., 2012).

However, whether survival times are dependent on gamma-knife

surgery itself is unknown.

A study of WBRT in combination with SRS showed
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improved local control of disease, although overall survival remained the same
(Tsao et al., 2012). However, another study found that omission of WBRT with SRS
led to progression of brain metastases (Dyer et al., 2012). Discrepancies between
the conclusions of these and many other studies highlight the complexity of the
disease and the need for a better understanding of the underlying mechanisms that
mediate response to the different available therapies.
Despite the dearth of therapies for brain metastasis, some new approaches are
beginning to show promise in the clinic. In patients with Her2 positive metastatic
breast cancer, Trastuzumab is the standard of care therapy. When administered
after the diagnosis of brain-metastatic disease, Trastuzumab extends overall
survival, presumably due to control of systemic disease and relatively easier access
to the brain in patients with a leaky blood-brain barrier (Mehta, Brufsky, & Sampson,
2012). In patients with an intact BBB, however, the drug’s molecular weight is too
large to gain access into the brain parenchyma. A recent Phase II clinical trial
tested the efficacy of systemic treatment with lapatinib in combination with
capecitabine as a first-line therapy for Her2-positive metastatic breast cancers
previously untreated for brain metastases. In this setting, the drug combination
achieved 65% response consisting of at least 50% volumetric reduction of brain
metastases, and all patients in the study achieved at least a partial response
(Bachelot et al., 2013).

Interestingly, patients treated with the combination of

lapatinib plus capecitabine received a 7 month increase in survival compared to
patients who were treated with trastuzumab-based therapy (Kaplan et al., 2013).
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Since it is believed that the efficacy of brain metastasis therapies are mostly limited
by the presence of the blood-brain-barrier, new techniques are under development
that focus on overcoming this obstacle.
ultrasound-mediated

blood-brain-barrier

One such new technique is called
disruption,

which

permeabilizes

the

BBB/BTB using focused ultrasound bursts and microbubbles in the circulation.
When combined with trastuzumab treatment, this technique was shown to
significantly extend the survival of rat model of brain metastasis of BT474 breast
cancer cells, compared to controls treated with trastuzumab alone (Park, Zhang,
Vykhodtseva, & McDannold, 2012).
1.7 The type-I Insulin-like growth factor signaling axis
Figure 2 shows the key components of the IGF-I Receptor signaling axis discussed
in the sections that follow.
1.7.I

IGF-I Receptor

The type I insulin-like growth factor receptor (IGF-IR) is known to promote
metastasis in several cancers, including those of the colon, pancreas, prostate, and
breast (Chitnis, Yuen, Protheroe, Pollak, & Macaulay, 2008; Lopez & Hanahan,
2002; Sachdev, Zhang, Matise, Gaillard-Kelly, & Yee, 2010). IGF-IR is composed of
an extracellular α ligand-binding subunit and an intracellular β subunit responsible
for signal transduction. IGF-IR shares 84% homology with the intracellular tyrosine
kinase domain of the Insulin Receptor (IR) (Fujita-Yamaguchi et al., 1986), and the
homology is even higher in the ATP-binding site, at 95%.

It is therefore not

surprising that IGF-IR receptors have been found to heterodimerize with IR and
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successfully transduce IGF-1-dependent downstream signals (Takata & Kobayashi,
1994).
IGF-IR is activated upon binding the IGF-I ligand, although IGF-II ligand, which
shares 62% amino acid sequence homology with IGF-I, can also bind and activate
the receptor with a two to fifteen-fold lower affinity (Fernandez & Torres-Aleman,
2012; Vashisth & Abrams, 2010; Yu & Rohan, 2000). Upon ligand binding, IGF-IR
becomes autophosphorylated at Tyr 1131, 1135, and 1136 in the β subunit and
subsequently recruits a host of proteins, including IRS-2, that activate signaling via
PI3K/AKT and Ras/Raf/MAPK pathways to promote cell motility and pro-metastatic
behavior in breast cancer cells (Chitnis et al., 2008; Jackson, Zhang, Yoneda, &
Yee, 2001; Kato, Faria, Stannard, Roberts, & LeRoith, 1994). It is common for
breast tumor tissues to express high amounts of IGF-IR, although amplification at
the DNA level has been found in some cases as well (Adelaide et al., 2007).
1.7.II

IGF-I and IGF-II ligands

In models of breast cancer bone metastasis, IGF-I ligand promotes motility of bonemetastatic cells through IGF-IR activation (Yoneda, Williams, Hiraga, Niewolna, &
Nishimura, 2001), and bone-derived IGF-1 can activate the process of bone
metastases in breast cancer in a paracrine manner (Hiraga et al., 2012). Inhibition
of astrocyte-derived IGF-1 ligand was shown to reduce in vitro growth and adhesion
of a brain metastatic variant of MDA-MB-435 breast cancer cells (Sierra et al.,
1997).
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In breast cancer patients, phosphorylated IGF-IR associates with poor survival, and
a recent study further showed that phosphorylation of IGF-IR at Tyr 1135/1136 is
correlated with brain metastases of breast and lung cancers (Improta et al., 2011;
Law et al., 2008). However, the biological significance of IGF-IR activation in brain
metastases of breast cancer has not been addressed to date.
1.7.II.A IGFBP3
The regulation of IGF-IR signaling is complex and not yet fully understood; however,
it is well established that the IGF-IR signaling axis can be dysregulated by altered
expression of the IGF ligands and IGF-binding proteins. The insulin-like growth
factor binding protein-3 (IGFBP3) is the major binding protein and regulator of IGF-1
ligand bioavailability and has been reported to inhibit as well as potentiate the
activity of IGF-IR signaling in different cancers (Firth & Baxter, 2002; Martin &
Baxter, 2011; Schedlich & Graham, 2002). In the least malignant breast cancer cell
lines, IGFBP3 plays an inhibitory role as a tumor suppressor, and this function is
reversed in highly malignant breast cancer cells which express higher levels of
IGFBP3 (Schedlich & Graham, 2002). IGFBP3 also promotes migration in breast
cancer cells (O'Han, Baxter, & Schedlich, 2009). In melanoma metastasis, IGFBP3
is overexpressed in metastatic tissues and is associated with malignant progression
(Xi et al., 2006). IGFBP3 was also shown to stimulate IGF-IR phosphorylation
indirectly through activation of sphingosine kinase 1 (SphK1) and EGFR
transactivation (Martin & Baxter, 2011). Adding yet another layer of complexity is
the finding that IGFBP3 expression itself can be regulated by IGF-1 ligand through
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PI3K/AKT signaling in mammary epithelial cells, suggesting that the IGF-IR axis is
self-regulated in an autocrine manner (Sivaprasad et al., 2004).
1.7.III

Insulin receptor substrate (IRS) proteins

Insulin Receptor substrate proteins act as signaling intermediates between cell
surface receptors, such as Insulin Receptor and Insulin-like growth factor receptor,
and downstream signaling molecules such as PI3K and MAPK pathways. They do
not possess kinase activity, but instead act as scaffolds upon which other signaling
molecules dock to form signaling complexes (Mardilovich, Pankratz, & Shaw, 2009).
The IRS protein family consists of several isoforms: IRS-1 was the first described as
a phosphoprotein that became phosphorylated in response to insulin stimulation,
IRS-2 was the second discovered, believed to be homologous to IRS-1, and IRS-4
which is only expressed in the brain, thymus, liver and kidney (Shaw, 2011).
The two most significant IRS isoforms in normal physiology are IRS-1 and IRS-2,
and they perform essential complementary roles in the regulation of glucose
metabolism (Taniguchi, Ueki, & Kahn, 2005).

Knockdown of IRS-1 in livers of

normal mice resulted in accumulation of gluconeogenic enzymes and increased
blood sugar levels, whereas IRS-2 knockdown resulted in upregulation of lipogenic
enzymes and accumulation of hepatic lipid (Taniguchi et al., 2005). The general
consensus about the roles of IRS proteins in cancer is that IRS-1 and IRS-4
associate with tumor growth and cell proliferation, while IRS-2 promotes invasion
and motility (Mardilovich et al., 2009). In breast cancer metastasis specifically, IRS-
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1 appears to be a metastasis suppressor while IRS-2 promotes the metastatic
process (Gibson, Ma, & Shaw, 2007).
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Figure 2

IGF-1R Pathway

	
  
Fig. 1. Key components of the IGF-1R pathway. The ligands IGF-1 and IGF-2 are both capable of binding and stimulating the catalytic activity of the IGF-1R.
Bioavailability of IGF-1 is modulated by a family of IGFBPs, whereas bioavailability of IGF-2 is modulated both by the IGFBPs and by binding to the
IGF-2R, an event that leads to receptor-mediated internalization and degradation of IGF-2 in lysosomes. Upon binding by either IGF-1 or IGF-2,
the IGF-1R undergoes receptor cross-linking and autophosphorylation, leading to the creation of multiple docking sites for the adaptor proteins IRS-1,
IRS-2, and Shc. IRS-1 and IRS-2 binding results in activation of the class I phosphatidyl inositol 3′ kinase, whose catalytic activity is the conversion of
PIP2 to the lipid second messenger PIP3. This event recruits the AKT family of kinases to the plasma membrane, where they can be phosphorylated and
activated by PDK1 and the mTOR-containing complex mTORC2. Activated AKT then mediates a host of cell signaling events, including disinhibition
of the mTORC1 complex and increased protein synthesis and cell growth, increased conversion of glucose to glycogen via inhibition of GSK-3β, and
increased proliferation and survival by activation or inhibition of key effectors such as the Foxo transcription factors, p27, BAD, and BCL-2. In contrast,
Shc binding to activated IGF-1R results in stimulation of the RAS/MAP kinase pathway, which also leads to increased cell proliferation.

domain, and that the insulin receptor A (IR-A) isoform,
in particular, is capable of binding IGF-2 with high affinity and mediating mitogenic signaling and survival (9).
In addition, IGF-1R is capable of forming heterodimers
with insulin receptor that seem to mediate similar signaling events to IGF-1R homodimeric receptors (10).
Several lines of evidence have established a role for the
IGF-1R pathway as an important target for cancer therapy.
A seminal finding was the observation that expression of
IGF-1R is required for neoplastic transformation by a number of cellular and viral oncogenes, including SV40 large
T antigen, HRAS, and epidermal growth factor receptor
(EGFR), suggesting an obligatory role between expression
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of this receptor and the acquisition of a transformed phenotype (11, 12). IGF-1R is also highly expressed in a wide variety of human cancers (13), and in rare cases is found to be
amplified at the DNA level (14). This overexpression seems
to have functional consequences, in particular the ability
to block apoptosis induced by a variety of agents or adverse tumor microenvironments (15–17), and can also
confer invasive and metastatic capability in a mouse
model of pancreatic tumorigenesis (18). Epidemiological
and functional studies have also implicated the ligands
IGF-1 and IGF-2 in various aspects of cancer biology. In
particular, elevated levels of circulating IGF-1 have been
associated with increased risk of developing breast, prostate,
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Figure 2. Key components of the IGF-IR pathway.
The IGF-1 and IGF-2 ligands are both capable of binding and stimulating the
catalytic activity of the IGF-IR. Bioavailability of IGF-1 is modulated by a family of
IGFBPs. Upon binding either IGF-1 or IGF-2, the IGF-IR undergoes receptor crosslinking and autophosphorylation, leading to the creation of multiple docking sites for
the adaptor proteins IRS-1, IRS-2 and SHC. IRS-1 and IRS-2 binding results in
activation of the class I PI3 Kinase, whose catalytic activity is the conversion of
PIP2 to the lipid messenger PIP3. This event recruits the AKT family of kinases to
the plasma membrane, where they can be phosphorylated and activated by PDK1
and the mTOR-containing complex MTORC2. Activated AKT then mediates a host
of cell signaling events, including disinhibition of the mTORC1 complex and
increased protein synthesis and cell growth, increased conversion of glucose to
glycogen via inhibition of GSK-3B, and increased proliferation and survival by
activation or inhibition of key effectors such as the FOXO transcription factors, p27,
BAD, and BCL-2. In contrast, Shc binding to activated IGF-IR results in stimulation
of the RAS/MAP kinase pathway, which also leads to increased cell proliferation.
Reprinted with permission from the American Association for Cancer Research,
provided by the Copyright Clearance Center. Copyright 2010, American Association
for Cancer Research.
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1.8 IGF-IR Inhibitors
IGF-IR has become an attractive target in the clinic over the last ten years, due to
its central role in cancer cell signaling. Various monoclonal antibodies and tyrosine
kinase inhibitors (TKIs) against IGF-IR are under investigation for treatment of solid
tumors (Chitnis et al., 2008). Most antibody-based IGF-IR inhibitors function by
blocking IGF-ligand binding to the receptor, decrease expression of IGF-IR at the
cell surface by mediating receptor internalization, and blocking intracellular signaling
primarily through PI3K/AKT pathway (Zha & Lackner, 2010). It is believed that
monoclonal antibodies are more specific, due to the amino-acid sequence similarity
of tyrosine kinase domain which makes specificity of TKIs a significant issue
(Rodon, DeSantos, Ferry, & Kurzrock, 2008). Initial results of IGF-IR treatment in
large clinical trials have not been as successful as hoped; however, anecdotal
cases of individual positive responses to IGF-IR therapies have encouraged
continued study into biomarkers that will enable selection of the best target
population (Gombos, Metzger-Filho, Dal Lago, & Awada-Hussein, 2012).
Picropodophyllin (PPP) is the only tyrosine kinase inhibitor currently available that
can discriminate between insulin receptor and IGF-IR (Girnita et al., 2004). PPP is
thought to inhibit IGF-IR by utilizing the MDM2 E3 ligase, which is known to
ubiquitinate the IGF-IR and causes its downregulation (R. Vasilcanu et al., 2008).
1.9 In vivo models of brain metastasis
Although brain metastasis studies typically rely on a combination between in vitro
and in vivo experimental approaches to formulate conclusions, some researchers
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have recently argued that in vitro and in vivo studies of the early steps of brain
colonization from the bloodstream should only be studied in vivo (Lorger, Lee,
Forsyth, & Felding-Habermann, 2011). Behavior of breast cancer cells in in vitro
cell adhesion and transendothelial migration analyses, for example, correlate poorly
with the behavior of the same cells in in vivo brain metastasis models. Since cells
are injected in the carotid artery, our model of brain metastasis circumvents many
anatomical barriers and primarily addresses the late stages of brain metastasis.
1.10

Statement of problem, hypothesis and project goals

The functional role of IGF-IR in primary breast cancer and breast cancer
metastasis has been well documented by others. Furthermore, Improta et. al. have
found a correlation of phosphorylated IGF-IR in patient samples of brain metastases
from breast cancer. However, whether IGF-IR directly plays a functional role in the
establishment of brain metastases has not been addressed. It is possible that IGFIR activation in brain metastases is a result of the highly malignant primary and/or
metastatic breast tumors from which they arise. However, it is also possible that
IGF-IR activation itself enables the establishment of breast cancer cells in the brain
by means of a survival advantage. Further studies are needed in order to discern
whether IGF-IR provides a survival advantage to breast cancer cells in the brain.
In the present study, we sought to address the biological relevance of IGF-IR
signaling in the metastasis of breast cancer to the brain. We hypothesized that
IGF-IR activation confers a metastatic advantage and enables the outgrowth
of breast cancer cells in the brain. Figure 3 depicts a model of our hypothesis.
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First, we test whether IGF-IR signaling plays a role in the metastatic potential of
brain-seeking breast cancer cells in vitro. Using an in vivo experimental brain
metastasis model, we found that ablation of IGF-IR expression can prevent the
outgrowth of brain metastases, suggesting that this signaling pathway merits further
study as a potential target for the treatment of breast cancer brain metastasis.
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Figure 3
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Figure 3. Model depicting project hypothesis.
Brain-seeking breast cancer cells overexpress the secreted form of IGFBP3, which
may enhance the bioavailability of IGF-1 or independently activate IGF-I Receptor
phosphorylation. Once activated, IGF-IR recruits docking proteins such as IRS-2,
which enable the assembly of protein complexes that transduce signaling
downstream through the PI3K/AKT pathway. IGFBP3 may also modulate the brain
microenvironment in a paracrine manner, but future studies should explore that
possibility in further detail.
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CHAPTER 2
MATERIALS AND METHODS
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2.1 Cell Culture
All cancer cell lines were maintained at 37°C in a 5% CO2 incubator. Unless
otherwise noted, cells were cultured in complete medium containing DMEM/F12
with 10% fetal bovine serum (FBS) and penicillin/streptomycin. The human MDAMB-231Br (brain-seeking) cell line and its corresponding MDA-MB-231P (parental)
cells were contributed by Dr. Patricia Steeg and previously described (Yoneda et
al., 2001). The BT474 M1 (parental) and BT474 Br3 (brain-seeking) cell lines were
established by Dr. Dihua Yu (MD Anderson, Houston, TX) and a detailed
description of the BT474Br3 cell line will be published later by Dr. Yu’s group. Cell
lines were validated by STR DNA fingerprinting using the AmpFlSTR Identifiler kit
according to manufacturer instructions (Applied Biosystems). The STR profiles were
compared to known ATCC fingerprints (ATCC.org), to the Cell Line Integrated
Molecular Authentication database (CLIMA) version 0.1.200808 (Nucleic Acids
Research 37:D925-D932 PMCID: PMC2686526) and to the MD Anderson
fingerprint database. The STR profiles matched known DNA fingerprints or were
unique. Cells were incubated with 50 ng/mL human recombinant IGF-1 (#I3769,
Sigma) for the indicated time points in ligand-stimulation experiments.

2.2 Immunoprecipitation and Western blotting
Equal numbers of cells per sample well were seeded and cultured in complete
medium and/or treated as specified. For analysis, cells were washed with PBS,
trypsinized, and pelleted. Equal amounts of protein were resuspended in IP binding
buffer (10x RIPA containing 0.5 M Tris-HCl (pH 7.4), 10% NP-40, 1.5 M NaCl, and
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10 nM EDTA). Either Rabbit IgG (#sc-2027, Santa Cruz Biotechnology) or anti-IGFIRβ (#sc-462, Santa Cruz Biotechnology) were added at 4°C overnight. Lysates
were incubated with Protein G agarose beads for 4 hr at 4°C, pulled down by
centrifugation, and then washed extensively with IP binding buffer containing
protease and phosphatase inhibitors. Immunoprecipitates were denatured using
sample buffer containing β-mercaptoethanol, centrifuged, and the protein-containing
supernatants were then analyzed by SDS-PAGE. Membranes were incubated with
anti-IGF-IRβ-pY1131/InsRβ-pY1146 (#3021, Cell Signaling Technology), anti-IGFIRβ-pY1135 (#3918, Cell Signaling Technology), and anti-p-Tyr-100 (#9411, Cell
Signaling Technology) to measure phosphorylation level of IGF-IR. For IP-Western
input controls and all other samples analyzed by SDS-PAGE, wells were loaded
with 70 µg of protein. Western blot membranes were probed with anti-IGFBP3 (C19; #sc-6003, Santa Cruz Biotechnology), anti-AKT (#9272, Cell Signaling
Technology), anti-pAkt (S473; #9271, Cell Signaling Technology), anti-S6K1 (#sc230, Santa Cruz Biotechnology), anti-pS6K1 (T389; #9205, Cell Signaling
Technology), and anti-tubulin (#T5168, Sigma). For IGFBP3 Western blots, 48-hr
conditioned medium was collected and concentrated 40-fold using Millipore Amicon
Ultra-4 centrifugal filters (Fisher). Equal protein amounts were loaded into each well
of an SDS-PAGE.

2.3 Flow Cytometry
IGF-IR phosphorylation was measured by flow cytometry. Cells were prepared as
previously described (Krutzik & Nolan, 2003). Briefly, cells were serum-starved for
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24 hr and then fixed for 10 min at room temperature with 1.5% paraformaldehyde by
adding it directly into the medium used to collect cells after trypsinization. Cells were
pelleted, permeabilized by adding ice-cold methanol and vortexing vigorously, and
then incubated for 10 min at 4°C. Cells were then washed twice with staining buffer
(PBS containing 1% BSA) and resuspended in staining buffer at 500,000 cells per
100 µl. Finally, cells were stained with AlexaFluor 647 mouse anti-IGF-1 Receptor
(pY1131; #558588, BD Biosciences) and analyzed using the BC Gallios flow
cytometer. Unstained cells were used as a control. All data were analyzed using the
FlowJo version X software.

2.4 Production of stable cell lines
MDA-MB-231Br cells were first transduced with the luciferase expression vector
pLenti CMV V5-LUC Blast w567-1 (plasmid #21474, Addgene) and the selected
using blasticidin. Stable IGF-IR knockdowns (shIGFR) were obtained by
transfection of MDA-MB-231Br cells with two lentiviral pLKO.1 constructs containing
shRNA against IGF-IR target sequences, GAGACAGAGTACCCTTTCTTT and
GCCGAAGATTTCACAGTCAAA

(TRCN0000121135

and

TRCN0000039675,

respectively, Open Biosystems). MDA-MB-231Br control cells (Vector) were
obtained by stable transfection with a pLKO.1 puro empty vector control plasmid
(Sigma). Luciferase, shRNA, or control constructs were co-transfected with lentiviral
packaging plasmids into 293T cells, and viral particles were harvested at 24 and 48
hr post-transfection. MDA-MB-231Br cells were infected with virus for 48 hr in the
presence of 5 µg/mL polybrene. Luciferase-expressing cells were first selected by
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incubation in complete medium containing blasticidin (2 µg/ml) for 2 weeks. After
stable luciferase-expressing MDA-MB-231Br cells were obtained, shRNA and
control vector infections were carried out and stable clones were selected using
culture medium containing puromycin (2 µg/ml) for 2 weeks. Knockdown of IGF-IR
was verified by Western blot. Luciferase expression was measured using the IVIS
imaging system to ensure all cell lines retained similar expression level.

2.5 Wound-healing assays
MDA-MB-231Br shIGF-IR or shControl stable cells were seeded in a Costar 12-well
dish (Sigma CLS3513) and cultured until confluent. A wound was introduced using
a 200-µl pipette tip, and cell migration was monitored using the Zeiss Axiovert 200M
time-lapse microscope and 10x phase contrast objective. Images of specific
positions were taken at 30-min intervals over 24 hr and recorded using the
AxioVision 4.6 software. Relative migration was calculated by measuring wound
area at different time points using ImageJ.

2.6 Intracarotid mouse model of experimental brain metastasis
Female Swiss nu/nu mice 8 weeks of age were purchased in-house from MD
Anderson’s Department of Veterinary Medicine and Surgery – ERO Animal
Resources. Mice were anesthetized with ketamine/xylazine and inoculated with
200,000 MDA-MB-231Br-shControl, -shIGFIR (B) or -shIGFIR (F) cells in 100 µl
HBSS via injection into the right common carotid artery. Cells were verified to have
a minimum of 95% viability prior to inoculation in mice. Development of brain
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metastasis was observed once weekly by luciferase imaging using the IVIS imaging
system by Caliper Life Sciences.

For imaging, mice were anesthetized by

isofluorane/O2 and injected intraperitoneally with 100 µL D-luciferin (Caliper Life
sciences). Ten minutes after D-luciferin injection, images of brain metastases were
captured using the Living Image 3.2 software. To obtain brain tissues, mice were
euthanized according to animal facility guidelines under CO2 asphyxiation followed
by cervical dislocation. Brains were excised immediately following euthanasia and
fixed in 10% neutral buffered formalin 24-48 hr at room temperature. Samples were
then washed thoroughly with PBS and cut into sections across the coronal plane.
Brain cross sections were paraffin embedded for analysis by immunohistochemistry
(IHC). All animal procedures were performed under the guidelines approved by the
Institutional Animal Care and Use Committee (IACUC) at MD Anderson Cancer
Center.

2.7 Immunohistochemistry (IHC)
For IHC, a modified immunoperoxidase staining method from the avidin-biotin
complex technique was used as described previously (Xia et al., 2004). Slides (4
µm thick) were first deparaffinized. Following antigen retrieval, the slides were
digested with 10 mM Tween 20 citrate buffer (pH 6.0). The endogenous peroxidase
activity was blocked by incubation in 0.3% hydrogen peroxide. The slides were then
blocked with 10% normal goat or horse serum for 30 min and incubated overnight
with primary antibodies, including anti-IGF-IR pAb (1:80 dilution; Santa Cruz
Biotechnology), anti-IGF-IR pAb (1:50; Cell Signaling Technology), anti-phospho-
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AKT (Ser473; 1:100; Cell Signaling Technology), anti-ki-67 pAb (ready to use;
Zymed); and anti-GFAP pAb (1:50; Cell Signaling Technology). After primary
antibody

hybridization,

slides

were

incubated

with

biotinylated

secondary

antibodies, followed by incubation with avidin-biotin-horseradish peroxidase
complex (Vector Laboratories). Antibody detection was performed with the 0.125%
aminoethylcarbazole chromogen (AEC) substrate solution (Sigma). The slides were
counterstained with Mayer’s hematoxylin (Sigma) and then mounted. For the
negative control, all incubation steps were identical except that PBS was used
instead of primary antibody. For the positive control, a previously identified strongly
staining tumor tissue section was used. The prepared slides were examined by light
microscopy. To ensure absolute objectivity of these IHC studies, experienced
pathologists, who stained and evaluated primary tumor sections, conducted the
experiments. The slides in which there was a scoring discrepancy >10% were reevaluated and reconciled on a two-headed microscope.

2.8 Cell cycle analysis
Equal cell numbers were seeded in complete medium overnight and were either
untreated or treated with picropodophyllin (Sigma) at 1 µg/mL for 48 hr. Cells were
then washed with PBS, trypsinized, and fixed in 70% ethanol for 24 hr.

After

fixation, cells were washed twice with PBS and incubated with 40 µg/ml propidium
iodide to stain DNA and 0.5 µg/ml RNAseH to degrade RNA to prevent it from being
included in the cell cycle analysis. Cell cycle was then analyzed using the BC
Gallios flow cytometer.
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2.9 Quantitative real-time PCR of IGFBP3
RNA from MDA-MB-231P and MDA-MB-231br cells was extracted using the Qiagen
RNEasy mini kit (Qiagen). cDNA was obtained by using the SuperScript FirstStrand System for RT-PCR (Life Technologies). Real-time PCR reactions were
prepared with 1x iQ SybrGreen Supermix (Bio-Rad) and 0.250 nM forward and
reverse primers. Cycling conditions consisted of annealing, amplification and melt
steps using the Applied Biosystems Veriti real-time PCR thermal cycler. Relative
gene expression was calculated by dividing the IGFBP3 expression value by the
HPRT1 expression value.

2.10

Transwell migration and invasion assay

Migration assays were performed using a 24-well transwell plate (Corning) and
invasion assays were performed using the 24-well BD BioCoat Matrigel Invasion
Chambers (BD Biosciences) according to the manufacturer’s instructions. MDA-MB231P (25,000) or

MDA-MB-231Br (40,000) cells were seeded in the chamber

inserts and allowed to migrate for 24 hr. Migrated cells were fixed with 4%
paraformaldehyde, stained with crystal violet (0.1% in ethanol), and counted.
Experiments were performed a minimum of 3 times in triplicate, and 5 fields of cells
were counted at 10x magnification per chamber insert.

2.11

Proliferation assays

MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay of shIGFIR and shControl cells was performed by seeding cells overnight at a concentration
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of 10,000 cells per well in a 96-well plate. After 24, 48, and 72 hr, MTT reagent was
added and cells were incubated at 37°C in 5% CO2 for 4 hr. Medium was then
aspirated, and cells were lysed with DMSO and shaken gently for 1 hr at room
temperature

before

measuring

the

optical

density

at

595

nm

with

a

spectrophotometer. The growth of shIGF-IR stable transfectants was also measured
by seeding cells at a concentration of 100,000 cells per well in a 6-well dish and
counting cells using the Z1 Coulter Particle Counter (Beckman Coulter). All wells
for MTT Assay and cell counting experiment were seeded in triplicate and
experiments performed a minimum of 3 times.

2.12

Statistical analysis

Significance in the brain metastasis-free survival curve was calculated using the
Gehan-Wilcoxon test. All other samples were analyzed using a two-tailed student’s t
test. Results with p < 0.05 were considered statistically significant.
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CHAPTER 3
THE ROLE OF TYPE I INSULIN-LIKE
GROWTH FACTOR RECEPTOR IN BRAINSEEKING BREAST CANCER CELLS
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3.1 Brain-seeking breast cancer cells express higher amounts of IGF-I
Receptor
In order to assess the importance of IGF-IR in our model system, we were
interested characterizing the expression profile of the receptor in our sets of 231
and BT-474 parental and brain-seeking cell lines. We performed a western blot of
total IGF-IR expression in 231P/Br and BT474M1/Br3 cells, and found that IGF-IR is
highly expressed in parental breast cancer cells, and expression is further increased
in brain-seeking sublines (Figure 4, top). Densitometric analysis was done using
ImageJ software to confirm the increase in IGF-IR expression normalized to tubulin
loading control (Figure 4, bottom). Increased IGF-IR expression in brain-seeking
cell lines suggested that this receptor may be enriched in highly metastatic cells.
3.2 Type I IGFR is autophosphorylated in brain-seeking breast cancer cells
Previous studies suggest that IGF-1 signaling and IGF-IR activation play a role
in the brain specificity of metastatic breast cancer (Improta et al., 2011; Sierra et al.,
1997). To determine the relevance of IGF-IR activation in our model of brain
metastasis, we characterized the activation profile of IGF-IR in parental MDA-MB231 (231P) and parental BT474 M1 breast cancer cells for comparison to their
respective brain-seeking sublines, MDA-MB-231Br (231Br) (Yoneda et al., 2001)
and BT474Br3. One of the current limitations of studying the phosphorylated form
of IGF-IR is the cross-reactivity of commercially available antibodies with
homologous phosphorylation sites on the insulin receptor. To circumvent this issue,
we first immunoprecipitated the IGF-IR β subunit with a specific antibody that does
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not cross-react with the insulin receptor, followed by immunoblotting with phosphoIGF-IR antibody against Tyr 1131, the earliest autophosphorylation site that is
absolutely required for IGF-I ligand-dependent IGF-IR function (Kato et al., 1994).
We found that 231Br and BT474Br3 cells had higher IGF-IR autophosphorylation
compared to the parental cells under normal growth conditions in complete medium
(Figures 5A and 5B). After normalizing each cell line’s phosphorylation signal to its
own total IGF-IR protein band, autophosphorylation of IGF-IR was increased by
27.4% and 21.6% in 231Br and BT474 Br3, respectively (Figures 5C and 5D).
To confirm this observation and to obtain a more detailed picture of the IGF-IR
activation profile in brain-seeking cells, we examined IGF-IRβ phosphorylation using
flow cytometry with an Alexa647-conjugated phospho-Tyr1131-IGF-IRβ antibody.
We found that both 231Br and BT474Br3 cell lines expressed more phosphorylated
IGF-IR than parental breast cancer cells under normal growth conditions in
complete medium (Figures 6A and 6B). An average of 36.4% of the 231Br cell
population was positive for phospho-Tyr1131 IGF-IRβ, compared to 14.6% of 231
parental cells (p < 0.005, Figure 6C, bottom left panel). Likewise, 81.9% of the
BT474Br3 cell population was positive for phospho-Tyr1131 IGF-IRβ, compared to
an average of 51.3% of the BT474 M1 parental cells (p < 0.05, Figure 6D, bottom
right panel). In addition to the percentage of phospho-Tyr1131 IGF-IR positive cells,
we also measured the median fluorescence intensity (MFI) of these populations,
which refers to the shift in overall intensity of the phospho-Tyr1131 IGF-IRβ signal.
Consistent with the results shown in Figure 6C and 6D, we observed an increase in
MFI of the 231Br and BT474Br3 cell populations compared to the parental cells
	
   36	
  

such that the MFI of 231Br cells was 3.24, compared to 2.1 in the 231 parental cells
(p < 0.0005; Figure 6E) while the BT474Br3 cell lines exhibited a similar trend with
an MFI of 7.29 compared to 4.38 in the parental BT474 cells (p < 0.05, Figure 6F).
One possible explanation for the higher phospho-IGF-IR observed in brain-seeking
cells in Figures 5 and 6 is the higher expression level of total IGF-IR protein
detected in whole cell lysates (Figure 4). The flow cytometry data indicated that
IGF-IR is autophosphorylated in a higher percentage of brain-seeking cells, and that
the mean intensity of IGF-IR phosphorylation in these cells is also higher.
Collectively, these findings demonstrated that the total protein level and
autophosphorylation of IGF-IR is higher in brain-seeking cells than in parental
breast cancer cells.
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Figure 4
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Figure 4.

IGF-IR expression profile of breast cancer cell lines and brain-

seeking subclones.
Top, Western Blot of total IGF-IR expression in 231P/Br and BT474M1/Br3 cells.
Bottom, densitometric analysis of IGF-IR bands from top panel, normalized to
Tubulin. ImageJ software was used for analysis.
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Figure 5
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Figure 5. IGF-IR is activated in brain seeking breast cancer cells.
A and B, Immunoprecipitates of IGF-IRβ from lysates of the parental MDA-MB-231
and BT474 breast cancer cells (231P, BT474 M1) and their respective brainseeking sublines (231Br, BT474 BR3), were analyzed by SDS-PAGE and
immunoblotted with antibodies against the IGF-IR Tyr1131 autophosphorylation
site. Cells were serum-starved overnight prior to lysis.
C and D, Quantification of IGF-IR-pY1131 expression in 231P/Br, BT474M1/Br3
cells after normalization to total IGF-IR IP band.

Phosphorylation of IGF-IR

increased in both brain seeking cell lines.
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Figure 6
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Figure 6. IGF-IR is activated in brain seeking breast cancer cells.
A and B, Flow cytometric analysis of IGF-IR activation in 231P & BT474 M1 breast
cancer cells and respective brain-seeking sublines, 231Br and BT474 Br3, shown in
Figure 5. Cells were serum-starved for 24h and stained with AlexaFluor 647phospho Y1131 IGF-IR antibody.
C and D, Quantitation of flow cytometric analyses of fluorescent cells per group is
shown below each panel. Values shown represent mean ± SEM from 3 replicates
(*, p < 0.05, ***, p < 0.0005).
E and F, Median Fluorescence Intensity shift captured by flow cytometric
measurement of parental and brain-seeking breast cancer cells stained with
Tyr1131-IGFR-Ax647 antibody. Values represent mean ± SEM (*, p < 0.05, ***, p <
0.0005).
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3.3 IGF-1 ligand stimulation drives migration and invasion in brain-seeking
cells
In order to test whether IGF-IR autophosphorylation and downstream functions
are mediated by IGF-1 ligand bioavailability in brain-seeking cells, we examined the
malignancy of brain-seeking cells under IGF-1 ligand stimulation.

In order to

evaluate whether 231P and 231Br cells are IGF-1-responsive, we first serumdepleted cells overnight in order to minimize the IGF-IR autophosphorylation
observed in Figure 5A. We then stimulated serum-depleted 231P and 231Br cells
with IGF-1 and immuniprecipitated of the IGF-I Receptor. In the IGF-IR
immunoprecipitates, we observed phosphorylation at Tyr1135 in the 231Br but not
231P cells, suggesting that brain-seeking cells are driven by ligand stimulation
(Figure 7A). We also examined the phosphorylation status of the insulin-receptor
substrate (IRS)-1 and -2, which are immediately activated upon IGF-IR activation.
IRS-2 is known to mediate motility and pro-metastatic behavior of IGF-IR in breast
cancer cells (Jackson et al., 2001), and indeed, only IRS-2 was phosphorylated
upon IGF-1 ligand stimulation in 231Br cells but not the parental cells (Figure 7B).
Downstream of IGF-IR, AKT was also phosphorylated at Ser 473 upon IGF-1 ligand
stimulation in 231Br cells but not 231P cells (Figure 7C).

The differential AKT

activation in the two cell types may be due to the serum-free medium used in this
experiment.

It is possible that the stimulation time (15 minutes) or IGF-1

concentration may not be high enough to induce AKT Ser 473 phosphorylation in
parental cells, but the 231 Br cells were sensitive to IGF-1 ligand due to IGF-IR
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overexpression. Taken together, these data suggest that the IGF-1 ligand activates
IGF-IR axis signaling molecules in brain-seeking cells.
Next, we performed a transwell assay to measure the response of 231Br cells
to IGF-1 ligand as a chemoattractant and found that overnight incubation with IGF-1
stimulated the migration of 231Br but not 231P cells under low serum conditions
(0.2% FBS DMEM; Figure 8A with quantification in the lower panel). Similarly,
231Br cells were more invasive in a matrigel invasion assay when IGF-1 ligand was
present as a chemoattractant (Figure 8B with quantification in the lower panel). In
our experience, only the 231Br cells responded to IGF-1 ligand stimulation under
low serum conditions. We speculate that under low serum conditions, IGF-1 ligand
stimulation is not sufficient to induce migration and invasion in 231 parental cells,
but 231Br cells are more sensitive to IGF-1 ligand stimulation due to their higher
levels of IGF-IR expression. Thus, we concluded that the IGF-IR signaling and prometastatic functions of brain-seeking cells are likely mediated by IGF-1 ligand and
further amplified by higher expression of IGF-IR protein.
Future studies should delve deeper into the molecular mechanisms of
increased IGF-IR expression of 231Br cells in further detail. Dysregulation of IGFIR expression in cancer is rarely a result of gene amplification or activating genetic
mutations. Rather, IGF-IR protein is regulated by a variety of tumor suppressor
proteins at the pre- and post-transcriptional level. For example, PTEN is known to
inhibit the synthesis of IGF-IR precursor, as well as inactivate AKT (Tanno et al.,
2001).

Loss of PTEN results in increased AKT phosphorylation as well as

increased IGF-IR protein translation (Tanno et al., 2001). Similarly, mutations of
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p53 can lead to increased IGF-IR promoter activity and mRNA transcript levels
(Werner, Karnieli, Rauscher, & LeRoith, 1996).

The IGF-IR promoter is also

repressed by BRCA1 (Maor, Abramovitch, Erdos, Brody, & Werner, 2000) and VHL
protein is a post-translational regulator by sequestration of HuR protein that results
in de-stabilization of IGF-IR mRNA (Yuen et al., 2007). p53, BRCA1, and VHL are
all known to downregulate IGF-IR transcription through interaction with Sp1
transcription factor and disrupting its binding to the IGF-IR promoter (Abramovitch,
Glaser, Ouchi, & Werner, 2003; Ohlsson, Kley, Werner, & LeRoith, 1998; Yuen et
al., 2007). Furthermore, Wilms Tumor Protein 1 (WT1) can also bind the IGF-IR
promoter directly on consensus sites on either side of the promoter through its zinc
finger domain and repress transcription (Werner et al., 1993).
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Figure 7
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Figure 7. IGF-IR activation is IGF-1 ligand-dependent in brain-seeking cells.
A, 231P and 231Br cells were serum-starved overnight, and then stimulated with 50
ng/ml IGF-1 for 15 min. IGF-IR was immunoprecipitated and then immunoblotted
with phospho-Y1135-IGF-IR antibody.
B, Immunoprecipitates of IRS-1 and IRS-2 proteins from serum-starved 231P and
231Br cells, unstimulated or stimulated with 50 ng/ml IGF-1 for 15 min.
C, Western blot analysis of whole cell lysates of 231P and 231Br cells after
stimulation

with

IGF-1.
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Figure 8
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Figure 8. IGF-1 stimulation drives in vitro migration and invasion in brainseeking breast cancer cells.
A, Transwell migration assay of cells incubated for 24h in low serum with or without
IGF-1 as a chemoattractant (top panel), quantitative analysis of relative cell invasion
(bottom panel).
B, Matrigel invasion assay of cells incubated for 24h in low serum with or without
IGF-1 as a chemoattractant (top panel), quantitative analysis of relative cell invasion
(bottom panel). Bars represent mean ± SEM.
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3.4 Secreted form of IGFBP3 is overexpressed in brain-seeking cells
Since the basal level of IGF-IR autophosphorylation in 231Br and BT474Br3
cells is much higher under normal culture conditions, we asked whether the IGF-IR
signaling axis is constitutively activated in an autocrine manner, either dependent or
independent of IGF-1 ligand. Along with IGF-1 ligand, IGFBP3 is one of the major
regulators of receptor activity in the IGF-IR signaling axis and a major binding
protein of IGF-1 ligand that both potentiates and inhibits its interaction with IGF-IR in
different cancers (Firth & Baxter, 2002; Martin, Lin, McGowan, & Baxter, 2009; Xi et
al., 2006). In Hs578T breast cancer cells, IGFBP3 promotes attachment and
survival on fibronectin (McCaig, Perks, & Holly, 2002), which is present in the
perivascular space of the brain microenvironment and known to promote the growth
of breast cancer cells in the brain (Carbonell, Ansorge, Sibson, & Muschel, 2009).
However, IGFBP3 has also been reported to modulate IGF-IR phosphorylation
independently of IGF-1 (Martin & Baxter, 2011; Schedlich & Graham, 2002). When
we examined the IGFBP3 mRNA expression level in 231Br cells, we found that it is
expressed 25-30 fold more than in 231P (Figure 9A). While IGFBP3 is traditionally
studied as a secreted protein, it is known to carry out some of its functions
intracellularly (Grkovic et al., 2012; Paharkova-Vatchkova & Lee, 2010). We first
analyzed the levels of secreted IGFBP3 by collecting the conditioned medium of
231P and 231Br cells. As a secreted protein, IGFBP3 exists in a non-glycosylated
form (29kDa), 2N-glycosylated (40kDa), and 3N-glycosylated (45kDa) forms (Firth &
Baxter, 1999). Based on the mRNA expression levels, we expected that the protein
levels of IGFBP3 would be higher in brain-seeking cells. Indeed, as shown in Figure
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9B, the wide IGFBP3 band indicates that all three glycosylated forms are highly
secreted in 231Br cells but were undetectable in 231P cells. We also analyzed the
levels of intracellular IGFBP3 and found no difference in expression between 231P
and 231Br cells (Figure 9C). These results suggest that IGFBP3 exerts its function
in 231Br cells in an extracellular autocrine manner.
We did not test the molecular mechanism behind IGFBP3 observed in our
model system, but it is known that IGFBP3 expression is stimulated by IGF-1 ligand
(57). IGFBP3 transcription is also regulated by promoter methylation and directly by
the p53 tumor suppressor binding both in the promoter region and intronically
(Hanafusa et al., 2005; Torng et al., 2009). Furthermore, Vitamin D Receptor (VDR)
binds the IGFBP3 promoter either alone or in association with Retinoid X, in order to
enhance its transcription (Peng, Malloy, & Feldman, 2004).

Interestingly, VDR

expression is also closely tied to IGF-IR signaling, and its expression is regulated by
IGF-1 ligand stimulation (Welsh et al., 2002). Therefore, we hypothesize that the
IGFBP3 is overexpression observed in 231Br cells is a result of an autocrine
positive feedback loop that is stimulated by enhanced IGF-IR pathway activation
through IGF-1 signaling. Further studies should test this hypothesis and elucidate
the molecular mechanism of IGFBP3 regulation in our model system.
3.5 Secreted IGFBP3 level correlates with autocrine IGF-IR activation in brainseeking cells
In this study, we sought to measure the intrinsic properties acquired by 231Br
cells that may be responsible for their enhanced ability to attach to and survive in
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the brain parenchyma to a greater degree than the 231 Parental cell line. Since we
observed a dramatic overexpression of IGFBP3 in 231Br cells, our goal was to
determine if IGFBP3 is functionally significant in promoting IGF-IR activation. To
test this, we knocked down the expression of IGFBP3 by transiently transfecting
231Br cells with two different IGFBP3 siRNAs (Figure 10A) and analyzed the
receptor autophosphorylation under normal growth conditions in complete medium.
Knockdown of IGFBP3 by two siRNAs potently inhibited IGF-IR Tyr phosphorylation
(Figure 10B). A similar inhibitory effect was observed by flow cytometry on the
phosphorylation of Tyr-1131-IGF-IR (Figure 10C), suggesting that IGFBP3
stimulates IGF-IR activation in an autocrine manner. Our study tested whether
IGFBP3 confers enhanced intrinsic IGF-IR activation, which may result in a survival
advantage when 231Br cells arrest in the brain parenchyma. Indeed, is possible
that the properties measured in this study may be equally important for metastasis
to the lymph nodes, bone, or lung for example. In order to specifically test the
importance of IGFBP3/IGF-IR signaling in brain-specific metastasis, it would be of
great interest to study effect of brain-derived IGF-1 ligand and IGFBP3 on IGF-IR
activation and 231Br cell migration/invasion. Although our study does not rule out
whether IGFBP3/IGF-IR pathway is also involved in other organ metastases of
breast cancer cells, it does highlight that in a heterogeneous population of breast
cancer cells that arrest in the brain parenchyma, those cells that contain IGFBP3
overexpression and subsequent IGF-IR pathway activation possess a survival
advantage in the brain microenvironment, as discussed in the following Chapter.
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The significance of IGFBP3/IGF-IR in the honing of breast cancer cells to the brain
should be the subject of future studies.
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Figure 9
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Figure 9. The secreted form of IGFBP3 is overexpressed in brain-seeking
breast cancer cells.
A, Real-time quantitative RT-PCR of IGFBP3 in 231P and 231Br cells. Data are
expressed as relative expression as a ratio to housekeeping gene HPRT1
expression.
B, Western blot analysis of secreted IGFBP3 protein in the conditioned medium of
231P and 231Br cells. Equal cell numbers were incubated in serum-free medium for
48 hr, and then the conditioned medium was collected and concentrated by 40-fold.
C, Western blot analysis of IGFBP3 protein in lysates of 231P and 231Br cells.
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Figure 10
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Figure 10. IGFBP3 knockdown results in decreased IGF-IR activation in brain
seeking cells.
A, Conditioned medium of 231Br cells transiently transfected with control or IGFBP3
siRNAs for 48 hr. Medium was concentrated by 40-fold and the protein expression
of IGFBP3 was analyzed using Western blot.
B, IGFBP3 knockdown downregulates IGF-IR phosphorylation. Cells were
transfected with either control or IGFBP3 siRNAs. IGF-IR was immunoprecipitated
(IP) and immunoblotted with phospho-Tyr antibody. Whole cell lysate (WCL) was
used as input control.
C, Flow cytometric analysis of 231Br cells after IGFBP3 knockdown. Cells were
transfected with either control or IGFBP3 siRNAs, and stained with AlexaFluor 647phospho Y1131 IGF-IR antibody. IGF-IR phosphorylation decreased in the siRNA
groups.
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CHAPTER 4
IN VITRO AND IN VIVO EFFECTS OF TYPE
I INSULIN-LIKE GROWTH FACTOR
RECEPTOR ABLATION IN BRAIN
SEEKING BREAST CANCER CELLS
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4.1 Transient knockdown of IGF-IR impairs wound healing in 231 brainseeking cells
In order to determine the biological relevance of IGF-I Receptor in brain-seeking
cells, we transiently transfected small interfering RNAs targeting the IGF-IR, and
evaluated the cells’ ability to close the gap in a wound healing assay. The woundhealing assay measures cell motility, as well as the degree of cell-cell and cellmatrix interactions in a cell monolayer (Rodriguez, Wu, & Guan, 2005). Figure 11A
is a control showing the efficiency of IGF-IR knockdown achieved by a universal
negative control siRNA, and two different IGF-IR siRNAs in both 231 parental and
brain-seeking lines. Figure 11B shows time-lapse images at 0, 12, 24, and 48
hours after introduction of the wound, and the 231Br cells transfected with IGF-IR
siRNAs had significantly impaired wound healing ability. The impaired ability of
cells to migrate at the leading edge of the wound also suggests that IGF-IR
knockdown may result in stronger cell-cell interactions between 231Br cells, and
thus render them less metastatic.
4.2

Transient

knockdown

of

IGF-IR

inhibits

IGF-1-mediated

AKT

phosphorylation in brain seeking cells.
To further validate whether IGF-IR knockdown plays a significant role in the
intracellular signaling of 231 brain-seeking cells, we transfected both parental and
brain-seeking 231 cells with IGF-IR siRNA and observed the effect of IGF-1 ligand
stimulation at 48 hours after transfection. As in Figure 7C, IGF-1 ligand stimulation
induced AKT Ser473 phosphorylation of 231Br cells but not parental cells.

In
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support of our hypothesis, IGF-IR siRNA inhibited AKT Ser473 phosphorylation in
231 Br cells (Figure 12). Therefore, we concluded that IGF-IR is important for
intracellular signaling of brain seeking breast cancer cells.
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Figure 11
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Figure 11. Transient knockdown of IGF-IR inhibits migration of brain-seeking
cells

A, Western blot of lysates from 231P and 231Br cells collected 72 hours after siRNA
transfection, the timepoint when siRNA shows the highest knockdown efficiency.

B, Wound healing assay of 231Br cells. Cells were transfected with Control siRNA
or IGF-IR siRNA #1 or #2, allowed to recover overnight and then re-seeded in a
monolayer overnight in a 12-well dish for wound healing assay. Scratch wound was
introduced at 48 hours after siRNA transfection, and wound closure was captured
by time-lapse microscopy over the next 36 hours.
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Figure 12
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Figure 12. Transient knockdown of IGF-IR downregulates IGF-1-induced AKT
activation
231P and 231Br cells were transiently transfected with control, IGF-IR #1 or IGF-IR
#2 siRNAs and stimulated with 50ng/mL of IGF-1 ligand for 15 minutes at 48 hours
after transfection. IGF-IR knockdown efficiency and AKT Ser473 phosphorylation
were observed by western blot.
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4.3 Stable knockdown of IGF-IR in brain-seeking breast cancer cells inhibits
cell proliferation in vitro
In order to study the relevance of IGF-IR in the development of brain metastasis
in vitro, and to follow up on our transient siRNA knockdown experiments (Figures 11
and 12), we developed a model system using 231Br cells stably expressing
luciferase and either empty vector (control) or IGF-IR shRNA. Of six sh-IGFR
knockdown cell lines generated, two IGF-IR knockdown clones, shIGF-IR (B) and
shIGF-IR (F), were selected for further characterization for comparison with the
vector clone (vector). We first verified that IGF-IR was knocked down and AKTSer473 phosphorylation was reduced (Fig. 13A). To further assess the in vitro
biological significance of IGF-IR knockdown in brain-seeking cells, we measured
cell proliferation of knockdown and control cells using an MTT assay. As shown in
Figure 13B, IGF-IR knockdown cells proliferated more slowly at all three time points.
Moreover, we measured the cell growth of IGFR knockdown and vector control cells
over a 72-hr period and calculated the total cell number. In agreement with the MTT
assay results, IGF-IR knockdown cells grew more slowly than vector control cells
(Fig. 13C).

4.4 Stable knockdown of IGF-IR in brain-seeking breast cancer cells
attenuates their migratory and invasive potential in vitro
Next, we examined the effect of IGF-IR knockdown on the in vitro properties
that are used as surrogate measures of metastatic potential of 231Br cells. We first

	
   66	
  

used a wound-healing assay to determine the effect of IGF-IR knockdown on
migration and found that IGFR knockdown cells were less efficient at closing the
wound than the vector control cells, indicating both reduced motility and an increase
of cell-cell adhesion in 231Br cells (representative images shown in Figure 14A and
quantification shown in Figure 14B). To determine the effect of IGF-IR knockdown
on the invasive potential of 231Br cells, we performed a matrigel invasion assay.
Consistent with our hypothesis, we found that IGF-IR knockdown indeed attenuated
the invasiveness of 231Br cells (representative images shown in Figure 14C and
quantification shown in Figure 14D). Taken together, these data demonstrate that
the loss of IGF-IR expression and subsequent inactivation of its downstream
signaling molecules attenuate the vitro invasive phenotypes, including proliferation,
migration/motility and invasiveness, while enhancing in vitro cell-cell adhesion of the
brain-seeking cells.
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Figure 13
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Figure 13. IGF-I Receptor knockdown in brain-seeking breast cancer cells
suppresses proliferation in vitro.
A, Immunoblot of IGF-IRβ and AKT total and phospho-Ser473 expression in 231Br
cells stably transfected with control shRNA (vector) or IGF-IRβ shRNA (shIGF-IR B
and F clones).
B, MTT assay of control and IGF-IR beta knockdown cells at 24, 48 and 72 hr.
Values represent mean ± SEM.
C, Vector control and shIGF-IR 231Br cells were seeded 100,000 cells per well and
were counted after 72 hr.
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Figure 14
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Figure 14. IGF-I Receptor knockdown in brain-seeking breast cancer cells
suppresses cell migration and invasion in vitro.
A, Wound-healing assay of vector and shIGF-IR 231Br cells. Images are
representative of triplicates at 0 and 21 hr.
B, Quantitative measurement of wound closure area from (A). Data were calculated
from one representative experiment out of three performed.
C, Matrigel invasion assay of vector and shIGF-IR 231Br cells performed in triplicate
over 24 hr with complete medium as a chemoattractant.
D, Quantitative analysis results of one representative experiment out of three
performed in triplicate from (C). Values represent mean ± SEM.
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4.5 IGF-IR knockdown delays the outgrowth of brain metastases in vivo
To further characterize the functional consequences of IGF-IR knockdown on
the development brain metastasis in vivo, we performed an experimental brain
metastasis assay as described in Chapter 2. Stable 231Br-Vector, 231Br-shIGF-IR
(B), and 231Br-shIGF-IR (F) cells were inoculated in the carotid artery of female
swiss nu/nu mice, and brain metastasis development was monitored for 12 weeks.
After the first 4 weeks, mice in the vector group developed physiological symptoms
of brain metastases, such as weight loss, crouching, lethargy and/or disorientation.
Figure 15 shows representative bioluminescence images of brain metastasis
formation in mice from each experimental group during weeks 1-4. Mice inoculated
with 231Br cells with IGF-IR knockdown demonstrated significantly longer survival
than those in the vector group (Figure 16A). Mice in both knockdown groups also
developed brain metastases, albeit significantly later than the vector group (p <
0.05). The vector group mice had a median survival of 46 days while the shIGF-IR
(B) and shIGF-IR (F) groups had median survival of 77 days and 55.5 days,
respectively (Figure 16B).

4.6 H&E and IHC analysis of mice that developed brain metastases
Brain sections of representative mice from each group (n=3 each Vector and
shIGF-IR (B); n=2 shIGF-IR (F)) were also analyzed by H&E staining (Figure 17A)
and IHC for the expression of IGF-IR (Figure 17B) and AKT-pSer473 (Figure 17C)
proteins. All mice included in the analysis were sacrificed at later time points (5-10
weeks after intracarotid inoculation).

H&E staining revealed visible brain
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metastases in most brain sections analyzed, although metastases from the IGF-IR
knockdown groups were generally smaller in size than the vector group (Figure
17A) with the exception of one sample from the shIGFR (B) group (not shown).
Most metastases expressed IGF-IR protein (Table 1) although metastases in the
shIGF-IR (B) and shIGF-IR (F) groups expressed lower levels of IGF-IR protein than
the vector group (Figure 17B).

Expression of AKT-pSer473 likewise correlated

positively with IGF-IR expression levels, with the vector group expressing the
highest level of AKT-pSer473 and IGF-IR knockdowns expressing the lowest
(Figure 17C). These results imply that in a heterogeneous starting population of
IGF-IR knockdown cells, those that retain IGF-IR and AKT-pSer473 expression are
able to survive and establish tumors within the brain microenvironment in a process
of positive selection.

4.7 Brain metastases induce reactive astrocytes
Furthermore, it has previously been reported that metastatic brain tumors cause
the activation of astrocytes in the brain microenvironment, resulting in the support of
tumor growth and vascularization (Yoshimine et al., 1985). The expression of glial
fibrillary acidic protein (GFAP) is a marker of this astrocytic activation, and IHC
staining revealed that the brain tissue surrounding brain metastases expressed high
amounts of GFAP (80% positive cells control group, 52%-58% positive cells shIGFIR groups, Table 1 and Figure 18). Remarkably, approximately 5-10% of GFAP
positive cells infiltrated the edges of the tumor, suggesting that the activation and
infiltration of astrocytes is associated with the growth of IGF-IR positive brain tumors
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(Figure 18, white arrows). Interestingly, studies by Fidler et al. found that reactive
astrocytes play a role in the resistance of melanoma cells to chemotherapy (Q. Lin
et al., 2010). Future studies should investigate the functional significance of GFAP
activation and its implications on the effect of tumor cell modulation of the brain
microenvironment.

4.8 IGF-IR positive brain metastases highly express nuclear proliferation
marker ki-67
In addition to IGF-IR expression, the metastases we detected also expressed
the nuclear proliferation marker ki-67 (Figure 19). Tumors from the control group
had an overall higher percentage of ki-67 positive cells compared with those from
the shIGF-IR (B) and shIGF-IR (F) groups (Table 1). Although the IGF-IR
knockdown cells eventually formed brain tumors, these metastases were less
proliferative than the vector control tumors at the time of mouse morbidity.

4.9 Heterogeneous effects of IGF-IR knockdown on the growth of mammary
fat pad tumors
In order to determine whether IGF-IR knockdown in 231Br cells inhibited tumor
cell proliferation in vivo, we inoculated 231Br Vector and 231Br-shIGF-IR (B) and
231Br-shIGF-IR (F) into the mammary gland of nude mice. Tumors were measured
bi-weekly for 8 weeks and the diameters are shown in Figure 20. The group of mice
inoculated with 231Br-Vector cells behaved as expected, with tumor volumes
gradually increasing over time. The 231Br-shIGF-IR (B) experimental group had
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remarkably no tumor formation over the 8 weeks, while the 231Br-shIGF-IR (F)
group behaved very closely to the Vector group.

We hypothesized that the

difference in proliferation may be due to the different levels of IGF-IR knockdown in
each cell line. As shown in Figure 13A, the sh-IGFR (B) cell line had complete IGFIR knockdown, while the shIGF-IR (F) cell line did not have complete knockdown of
IGF-IR protein.

This suggests that even low amount of IGF-IR is sufficient to

support cell proliferation of 231Br cells in vivo, at least in the mammary fat pad.
Indeed, the IHC staining in Figure 21 confirms that the mammary fat pad tumors
from mice in the shIGF-IR (F) group expressed lower amounts of IGF-IR protein, but
developed normal mammary tumors as in the Vector group.
Thus, partial IGF-IR knockdown is not sufficient to prevent in vivo survival of
231Br cells. This result could offer an explanation why some of the mice inoculated
with both 231Br knockdown cell lines eventually developed brain metastases
(Figures 16), and why the observed metastases expressed IGF-IR (Figure 17). This
result also raises questions about our experimental brain metastasis model. In
particular, whether factors other than IGF-IR-driven proliferation and survival of cells
in vivo are at play in the development of brain metastasis, such as interactions with
the brain microenvironment and/or MET which could be necessary for successful
brain colonization.
In order to test whether the inhibition of mammary fat pad tumor formation in the
shIGF-IR (B) cell line was indeed due to the complete IGF-IR knockdown achieved
in this cell line, it would be useful to repeat the experiment side-by-side with
additional conditions. In particular, we could test our hypothesis that incomplete
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IGF-IR inhibition is insufficient for inhibition of in vivo cell proliferation in the
mammary fat pad by adding several 231Br-Vector control groups with the addition
of incremental doses of the IGF-IR inhibitor PPP. In this setting, there should be an
inverse relationship between tumor volumes and PPP concentrations if our
hypothesis is correct that IGF-IR expression level dictates 231Br cell survival and
proliferation in vivo. Confirmation of our hypothesis would imply that survival of
231Br shIGF-IR (B) cells in our brain metastasis model is a result of a re-expression
of IGF-IR protein in our shIGF-IR cell lines, perhaps by epigenetic modulation, since
we know that we started with a population with complete IGF-IR knockdown (Figure
13A). Another possibility is that IGF-IR is not the only factor dictating in vivo cell
proliferation and brain metastasis in our model, in which case microenvironmental
factors such as the induction of MET may be at play.

Both possibilities could

account for the differences in brain metastasis development evidenced in the
shIGF-IR (B) group, where 5 out of 8 mice (62.5%) eventually bypassed the barrier
posed by IGF-IR knockdown, and the remaining 3 mice (37.5%) never developed
brain metastases (Figure 16). We originally hypothesized that IGF-IR knockdown in
shIGF-IR (B) cells would result in complete inhibition of brain metastasis, but our
results suggest an epigenetic modulation of IGF-IR expression and perhaps other
IGF-IR-independent mechanisms of cell survival such as MET in the brain
microenvironment. Further testing using the experiment proposed in this section,
and the investigation of EMT/MET markers in our brain metastasis and mammary
fat pad models would help to discern between these two possibilities.
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Figure 15
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Figure 15. IGFR knockdown delays brain metastasis development in vivo.
Mice were anesthetized and injected with 200,000 231Br cells in the carotid artery;
231Br-Luc-Vector (n=9), 231Br-Luc-shIGF-IR (B) (n=8), and 231Br-Luc-shIGF-IR
(n=8). Mice were imaged the day after surgery to ensure cells were arrested in the
brain capillary. Brain metastasis progression was monitored weekly by imaging with
the IVIS imaging system following intraperitoneal administration of D-Luciferin.

	
   78	
  

Figure 16
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Figure 16. IGF-IR knockdown increases survival of mice bearing brain
metastases.
A, Survival curve of mice injected with 231Br cells stably expressing IGF-IR shRNA
or vector shRNA. Mice were monitored weekly and sacrificed when moribund.
shIGF-IR(B) and shIGF-IR(F) groups had significantly longer survival, p = 0.0012
and p = 0.0133, respectively.

B, Median survival of each group from (A).
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Figure 17
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Figure 17. IGF-IR knockdown delays brain metastasis in vivo.
H&E and IHC staining of representative brain metastases from each group.

A, H&E panels: dark red = tumor tissue; blue = nucleus; light red = negative.

B and C, IGF-IR and AKT-pSer473 panels, respectively: red = positive; blue =
nucleus. Images were taken at 200x and 400x magnification, as indicated.
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Figure 18
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Figure 18. IHC staining of GFAP of brain metastases of mice inoculated with
Vector, shIGF-IR (B) and shIGF-IR (F) 231Br cells. GFAP: dark red/brown =
positive; blue = nucleus; black arrows = tumor cells; white arrows = tumor-infiltrating
astrocytes. Images were taken at 200x and 400x magnification, as indicated.
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Figure 19
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Figure 19. IHC staining of ki-67 of brain metastases of mice inoculated with
Vector, shIGF-IR (B) and shIGF-IR (F) 231Br cells. Red = nuclear ki-67 staining.
Images were taken at 200x and 400x magnification, as indicated.
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Table 1. Summary of H&E and IHC staining of brain metastases of mice inoculated
with Vector, shIGF-IR (B) and shIGF-IR (F) 231Br cells. Higher IGF-IR and ki-67
staining appears to correlate with formation of larger metastases.
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Figure 20
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Figure 20. Tumor formation in the mammary fat pad is heterogeneous in IGFIR knockdown cell lines.

Female nude mice were inoculated with 231Br-Vector (n=10), 231Br-shIGF-IR (B)
(n=10), or 231Br-shIGF-IR (F) (n=10) cells in the mammary fat pad. Tumor growth
was measured bi-weekly for eight weeks beginning on the second week, and
average tumor volumes are plotted.
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Figure 21
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Figure 21. Tumor formation in the mammary fat pad from IGF-IR knockdown
cells is heterogeneous.
H&E and IHC staining of representative mammary fat pad tumors from each group.

A, H&E panels: dark red = tumor tissue; blue = nucleus; light red = negative.

B and C, IGF-IR: red = positive; blue = nucleus. Images were taken at 200x and
400x magnification, as indicated.
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4.10 Inhibition of the IGF-IR by picropodophyllin induces G2/M cell cycle
arrest and inhibits downstream signaling and biological function
Several monoclonal antibodies and TKIs against IGF-IR are currently under
study in the clinical setting and have shown promise in the treatment of solid tumors
(Chitnis et al., 2008). Picropodophyllin (PPP) causes an induction of cell cycle arrest
in the G2/M phase and is the only inhibitor that can specifically inhibit IGF-IR
without affecting the insulin receptor (Stromberg et al., 2006). PPP also leads to
inhibition of cell growth, migration and invasion, and metastasis in a PI3K/AKTdependent manner (Girnita et al., 2004; Menu et al., 2006; D. Vasilcanu et al.,
2004). We analyzed the effect of PPP on the cell cycle and demonstrated that PPP
induces an increase of cells in G2/M phase by 86% in 231Br cells and 35% in
BT474Br3 cells (Figure 22). This result is consistent with other published studies
that demonstrated arrest in the G2/M transition upon PPP treatment (Stromberg et
al., 2006),(Karasic, Hei, & Ivanov, 2010). However, PPP-induced G2/M cell cycle
arrest is an interesting phenomenon given that the IGF-IR’s major effect on the cell
cycle is not primarily exerted in G2/M, but in the G1/S transition. IGF-IR regulates
the G1/S transition by activation of PI-3K/Akt and/or ERK pathways, which leads to
Cyclin D1 and CDK4 expression and cell cycle progression (Lavoie, L'Allemain,
Brunet, Muller, & Pouyssegur, 1996). IGF-IR may also regulate the G2/M transition
by upregulation of Cyclins A and B, and cdc2 synthesis, but this function is not as
well documented (Furlanetto, Harwell, & Frick, 1994).
Concomitant with G2/M cell cycle arrest, PPP treatment of 231Br and BT474
Br3 cells potently blocked the activation of molecules downstream of IGF-IR in a
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dose-dependent manner, in particular the phosphorylation of AKT-Ser473 and
p70S6 kinase-Thr389 (Figure 23).

It is unlikely that inhibition of AKT

phosphorylation by PPP is responsible for the G2/M cell cycle arrest we observed,
since AKT is primarily involved in the G1/S transition. It is possible that the G2/M
cell cycle arrest resulted in less cycling cells and therefore a decrease in overall
AKT activation. Another explanation could be off-target effects of PPP treatment,
such as inhibition of the EGFR or c-Met receptors, which are both known to play a
role in the G2/M transition (Baker & Yu, 2001) (Factor et al., 2010). Further studies
should

address

whether

PPP-induced

G2/M

arrest

and

AKT

pathway

downregulation are linked, or a result of off-target effects in our cell lines.
In addition, PPP inhibited biological functions of the 231 brain-seeking cells in
which PPP-treated cells had impaired migration (Figure 24A, quantitation shown in
Figure 24B) and invasion (Figure 24C, quantitation shown in Figure 24D). PPP did
not significantly inhibit the migration or invasion of BT474 Br3 cells (Figure 24E),
which may be due to the low baseline in vitro metastatic properties of this luminaltype cell line. Perhaps overexpression of IGF-IR in BT474 M1 (parental) or BT474
Br3

cells

combined

with

PPP

inhibitor

experiments

using

IGF-1

as

a

chemoattractant would better address the significance of IGF-IR in these less
aggressive, yet still brain-seeking, breast cancer cells. Furthermore, treatment of
231 Parental and brain-seeking breast cancer cells with different concentrations of
PPP inhibited wound-healing (Figure 25A) and cell proliferation (Figure 25B), and
these effects were more pronounced in the brain-seeking cells that overexpress
IGF-IR. Thus, PPP inhibits cell migration and proliferation while enhancing cell-cell
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adhesion, similar to the effects achieved by siRNA and shRNA ablation of IGF-IR.
Taken together, these data indicate that IGF-IR-driven signaling could be potentially
targeted by PPP in highly invasive brain-seeking cells. Further studies should test
this

hypothesis

in

a

mouse

model

of

experimental

brain

metastasis.
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Figure 22
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Figure 22. Picropodophyllin induces G2/M cell cycle arrest in brain-seeking
breast cancer cells.

Cell cycle analysis by propidium iodide staining of brain-seeking cells (231Br and
BT474 Br3) treated with 1 µg/mL PPP for 48 hr.

	
   97	
  

Figure 23
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Figure 23. Picropodophyllin inhibits activation of IGF-IR downstream targets
in brain-seeking breast cancer cells.
Immunoblot of phospho-proteins activation downstream of IGF-IR in brain-seeking
cells treated with escalating concentrations of PPP for 24h.
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Figure 24

	
  
100	
  

Figure 24. Picropodophyllin inhibits migration and invasion in 231 brainseeking breast cancer cells.
A, Transwell migration assay of 231Br cells treated with 1 µg/mL PPP for 24 hr.
B, Quantitative analysis of relative number of migrating cells from (A).
C, Matrigel invasion assay of 231Br cells treated with 1 µg/mL PPP for 24 hr.
D, Quantitative analysis of relative number of migrating cells from (D).
All migration and invasion assays used complete medium as a chemoattractant.
Images shown are representative of one of three experiments performed. Bars
represent mean ± SEM.
E, Transwell migration and matrigel invasion assay of BT474 Br3 cells.
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Figure 25
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Figure 25. Picropodophyllin inhibits wound healing and proliferation in brainseeking breast cancer cells.

A, Wound healing assay of parental and brain-seeking 231 cells treated with
different concentrations of PPP. Brain-seeking cells have decreased wound healing
ability in response to PPP.

B, MTT assay of cells treated with PPP for 48 hours. Proliferation of brain-seeking
cells is more sensitive to PPP treatment than parental cells.
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CHAPTER 5
SUMMARY AND DISCUSSION
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5.1 Summary
The work described in this thesis is summarized in the model depicted in
Figure 32. In brief, the IGF-IR signaling axis was activated both endogenously and
in an IGF-1 dependent manner in brain-seeking subclones of breast cancer cell
lines. IGF-IR activation is determined by the level of total tyrosine phosphorylation
of the IGF-I receptor, and by the phosphorylation of specific tyrosine residues 1131
and 1135, which pertain to the kinase domain. IGF-IR activation was also evident
by the tyrosine phosphorylation detected in IRS-2, the scaffold protein immediately
downstream of IGF-IR that is known to activate migratory and invasive functions in
metastatic breast cancer cells. AKT, but not ERK, was also phosphorylated both
endogenously and upon IGF-1 stimulation of brain-seeking cells. We found that
IGF-IR activation was at least partially dependent on IGFBP3 protein, which is
highly secreted in 231Br cells but not in parental 231 cells. IGFBP3 knockdown
resulted in significant downregulation of IGF-IR tyrosine phosphorylation.
When we experimentally ablated IGF-IR protein in brain-seeking cells, either by
transient siRNA transfection or stable shRNA transfection, we observed a decrease
in the proliferation, motility and invasiveness of cells.

When injected into the

intracarotid artery of nude mice, these IGF-IR shRNA knockdown cells displayed a
delay in their colonization of the brain, which led to a significantly longer lifespan of
these mice that acquired brain metastases. The IHC staining confirmed that IGF-IR
expression was high in the control brain-seeking cells, but interestingly the brain
metastases formed from shRNA groups had retained or partially re-expressed IGFIR, although lower than the control groups. IGF-IR shRNA effects on mammary fat
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pad tumor growth did not behave as expected, with one knockdown group
completely unable to form tumors and the other producing equal tumor volumes as
the control groups. The IGF-IR inhibitor PPP caused G2/M cell cycle arrest as well
as dose-dependent downregulation of AKT phosphorylation and p70S6Kinase.
In a separate study aimed at better characterize the AKT activation profile
between brain-seeking and parental breast cancer cells, we found that AKT is
constitutively phosphorylated in the nucleus of brain-seeking cells, and this
phosphorylated form is stimulated by the IGF-IR signaling axis. Nuclear phosphoAKT was enhanced upon IGF-1 stimulation and downregulated in IGF-IR shRNA
knockdown cell lines. However, when stimulated with EGF-ligand or treated with
the EGFR inhibitor Tarceva, nuclear phospho-AKT remained unchanged.
Furthermore, we found that transient transfection with a combination of AKT1 and
AKT3 are the two major isoforms of AKT that are phosphorylated in the nucleus of
brain-seeking cells.
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Figure 26
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5.2 Discussion
An important step in the development of rational therapies for brain-metastatic
breast cancer is the identification of major molecular drivers of the disease. The
study presented here supports the notion that (A) the IGF-IR signaling axis is active
and mediates malignant phenotypes in brain-seeking breast cancer cells, (B) both
genetic and pharmacological inhibition IGF-IR decrease the malignancy of brainseeking cells in vitro, and remarkably (C) IGF-IR shRNA-expressing breast cancer
cells have a decreased ability to form brain tumors in an in vivo model of
experimental brain metastasis. The studies presented here support that IGF-IR
signaling is a driver of brain metastases, with important implications in which
therapeutic inhibition of this receptor may prevent or delay the establishment of IGFIR-positive metastatic brain tumors from breast cancer.
In our model system, 231Br and BT474Br3 cells expressed more of the
autophosphorylated form of IGF-IR.

This result is in agreement with previous

studies that found activated phospho-IGF-IR/IR and phospho-S6K are associated
with poor survival in patients with invasive breast cancer (Law et al., 2008).
Furthermore, phospho-IGF-IR and phospho-AKT were recently shown to correlate
with metastases of breast cancer to the brain in a cohort of 42 brain metastases
from breast and lung cancer patients (Improta et al., 2011). In our study, we found
constitutively activated IGF-I Receptor when cells were examined in normal serum
conditions (10%FBS/DMEM), concomitant with a baseline AKT phosphorylation at
Ser473, suggesting constitutive IGF-IR pathway activation (Figs. 5A, 5B, 12, 26).
This constitutive IGF-IR activation was abrogated when we eliminated the IGF-I
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Receptor through siRNA, shRNA, or by treatment with PPP (Figs. 11-14, 22-25).
Indeed, phosphorylated IGF-IR appears to be a recurrent theme in advanced breast
cancers, and our results further elucidated its biological significance.
We concluded that constitutive autophosphorylation of IGF-IR is likely due to
regulation by the autocrine components of the IGF-IR signaling axis, such as IGF-1
and IGFBP3. IGFBP3 was overexpressed in 231Br brain-seeking cells, and its
knockdown by siRNA resulted in a significant decrease of IGF-IR Tyr
phosphorylation. These findings led us to believe that IGFBP3 may enhance IGF-1
bioavailability and subsequently activate IGF-IR in our model system.

Various

studies suggest mechanisms of IGF-IR induction by IGFBP3, including signaling
through sphingosine kinase (Sphk) and cross-activation of IGF-IR and EGFR and
binding of IGFBP3 (Martin et al., 2009). However, further work is needed to confirm
the IGF-1 ligand-dependent function of IGFBP3 on IGF-IR.
To address the biological significance of IGF-IR, we constructed brain-seeking
231 cells stably expressing IGF-IR shRNA. Ablation of IGF-IR diminished the
proliferation, migration, and invasion of 231Br cells in vitro. Knocking down IGF-IR
delayed the outgrowth of brain metastases and extended the survival of mice
bearing brain metastases. When we examined the brains of mice bearing brain
metastases of shIGF-IR 231Br cells, we were surprised to find that these
metastases expressed IGF-IR, albeit at lower levels than the brain metastases from
the vector 231Br group. We speculate that in our model, the brain microenvironment
selected for, if not promoted, the survival of tumor cells with remaining expression of
IGF-IR.
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5.2.I Implications for brain metastasis in Her2+ and triple negative breast
cancer
The cause of brain metastasis remains elusive although 25 to 40% of patients
with Her2+ and triple-negative breast cancer (TNBC) have a significantly increased
likelihood of developing brain metastases (Duchnowska et al., 2012; Steeg et al.,
2011) (Hicks et al., 2006). Interestingly, the increased signaling of the IGF-IR has
been shown to associate with resistance of Her2+ breast cancers to trastuzumab
(Gallardo et al., 2012). A recent preclinical study showed the expression of an IGFIR gene signature in TNBC that consequently sensitizes this cancer subtype to antiIGF-IR therapy (Litzenburger et al., 2011). IGF-IR signaling was also shown to
promote the proliferation and survival of TNBC cells, and it was associated with
early tumor recurrence in TNBC patients when accompanied by PTEN loss
(Davison, de Blacquiere, Westley, & May, 2011; Iqbal, Thike, Cheok, Tse, & Tan,
2012). In addition, other groups have also suggested the reliance of TNBC cell lines
on IGF-1 signaling (Davison et al., 2011). It is worth noting that the 231Br cell line
used in our model system is a TNBC cell line, and our results support the notion
that IGF-IR might play a role in brain metastasis of TNBC. Future studies with
additional TNBC models should explore the role of IGF-IR in this aggressive subset
of breast cancers in further detail.

5.2.II Implications for pharmacological targeting of the IGF-IR signaling axis
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We found that PPP potently inhibited IGF-IR signaling in breast cancer cells in
vitro. A previous report identified that the major IGF-regulated process in the cell
cycle is upregulation of genes involved in the G2/M transition (Litzenburger et al.,
2011). Our findings confirmed that the same holds true in brain-seeking breast
cancer cells. Furthermore, in an intracranial xenograft model of glioblastoma, PPP
demonstrated ability to cross the blood-brain-barrier and cause tumor regression as
well as downregulation of p-AKT, suggesting its potential usefulness in brain
metastasis treatment (Yin et al., 2010). However, a recent study of drug delivery in
mouse models of breast cancer brain metastasis found the heterogeneity of bloodtumor-barrier permeability to be a major obstacle to drug efficacy, and further
validation of PPP in these mouse models is needed (Lockman et al., 2010). To our
knowledge, this is the first study to establish a clear biological role of the IGF-IR and
its activation in brain-specific metastases of breast cancer, suggesting that
dysregulated molecules along the IGF-IR signaling pathway play a significant role in
the establishment of brain metastasis. Further studies should pursue the utility of
IGF-IR inhibitors for the prevention and treatment of brain metastases of breast
cancer, particularly in a setting where the patient is refractory to other therapies.

5.2.III Implications of using human breast cancer cell lines in models of brain
metastasis
Our model of experimental brain metastasis consisted of injection of human breast
cancer cell lines that had been selected in vitro for their brain-seeking properties.
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Our model, therefore, may not be the best for studies of spontaneous brain
metastasis, or to study the early steps of brain metastasis when tumor cells leave
their primary and/or metastatic tumor site and the characteristics that attract these
cells to the brain as a metastatic site. Injection of the tumor cells into the carotid
artery of mice circumvents all of these early steps, and even the major anatomical
barrier of the lung that tumor cells encounter prior to reaching the brain. Therefore,
it is important to note that our model primarily deals with the effect of IGF-IR
knockdown in the ability of breast cancer cells to arrest and attach to the capillary
bed of the brain, cross the blood-brain-barrier, survive in the brain to establish
metastases and eventually cause morbidity due to tumor burden. Future studies
should fine-tune exactly which of these later steps of metastasis the IGF-IR is
involved in. For example, in vitro transendothelial migration assays using human
brain microvascular endothelial cells using IGF-1 as a chemoattractant would
provide clues about brain-derived IGF-1’s role in inducing breast cancer cells to
cross the blood-brain barrier, much like SDF-1 acts on the cell surface receptor
CXCR4. Co-culture studies of astrocytes and our IGF-IR-knockdown breast cancer
cells would yield more information about the crosstalk between breast cancer cells
with cells of the brain parenchyma in the activation of survival cues.
5.2.IV Implications of using epithelial vs. mesenchymal cell types in modeling
brain metastasis.
The MDA-MB-231 breast cancer cell line is a highly malignant and metstatic breast
cancer cell line from epithelial origin. Despite its epithelial origin, the 231 cell line
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behaves like an undifferentiated, mesenchymal cell type and in gene expression
profiling studies it was found to express mostly mesenchymal genes (CharafeJauffret et al., 2006). This is in contrast to the BT-474 cell line that is also from
epithelial origin but is more differentiated and has been classified into the luminal
subtype. Luminal cell types are believed to be less invasive than mesenchymal or
basal types due to the expression of the cell-fate differentiating factor GATA-3
(Asselin-Labat et al., 2007), although recent evidence suggests that luminal cell
types also possess the ability to initiate metastatic tumors (Kim et al., 2012). It is
important to note the difference in intrinsic behaviors between the 231 and BT-474
cell lines, because this may explain the differences we observed between the two
cell types in in vitro experiments in our model of brain metastasis. In Figure 24, for
instance, the migratory and invasive behavior of the 231Br cell line was inhibited by
treatment with the IGF-IR inhibitor PPP, while the migration of BT474 Br3 cells was
unchanged, and invasion was not as pronounced as in 231Br cells. Due to its noninvasive phenotype, the baseline metastatic potential of BT474 Br 3 cells is already
very low, which presents a challenge in experiments where a decreased metastatic
potential is expected. A more appropriate experiment for this cell type may be to
measure the increase in in vitro metastatic potential under exogenous
overexpression of IGF-IR.
5.2.V Role of EMT/MET and the brain microenvironment
Epithelial-to-mesenchymal transition (EMT) is the process by which tumor cells
originating in the epithelium degrade the extracellular matrix and separate from the
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tumor to become undifferentiated, mesenchymal-like cells with enhanced invasive
and metastatic ability (Gao, Vahdat, Wong, Chang, & Mittal, 2012; Kalluri &
Weinberg, 2009).
It was recently shown that mesenchymal-like 231 breast cancer cells can revert to
the epithelial phenotype in the metastatic organ microenvironment in a process
called MErT, or mesenchymal to epithelial reverting transition (Y. L. Chao, Shepard,
& Wells, 2010). MErT was achieved by re-expression of E-cadherin in the
metastatic tumor microenvironment, through a loss of methylation of the E-cadherin
promoter. It would be of interest to perform IHC studies of brain metastases arising
from 231Br cells, to test whether the brain microenvironment indeed induces the reexpression of E-cadherin in these cells, and whether IGF-IR has any part in this
process. Since IGF-IR knockdown reduced brain metastasis in our model system, it
would further strengthen our hypothesis that IGF-IR provides a survival advantage if
somehow as a result of IGF-IR knockdown, E-cadherin re-expression was inhibited
as well. Previous studies have found that IGF-IR overexpression in breast cancer
cells promotes E-cadherin dependent cell-cell adhesion, cellular aggregation and
survival (Guvakova & Surmacz, 1997). Also, IGF-IR knockdown in breast cancer
cells resulted in a decrease of E-cadherin expression and destabilization of the Ecadherin-catenin complex, which is responsible for epithelial cell-cell adhesion and
maintenance of the tumor architecture (Pennisi, Barr, Nunez, Stannard, & Le Roith,
2002; Wijnhoven, Dinjens, & Pignatelli, 2000).
5.3 Future Studies
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This dissertation deals primarily with characterization of the intrinsic metastatic
properties of brain-seeking breast cancer cells, the autocrine signaling that
enhances metastatic properties, and the role of IGF-IR expression in the later
stages of the metastatic process in vivo. Future studies should address the
interactions between IGF-IR expressing breast cancer cells and other cell types in
the brain microenvironment, such as vascular endothelial cells, astrocytes, and
pericytes. The role of brain-derived IGF-1 and IGFBP3 in the promotion of
metastatic cell survival is also of interest, as is the effect of breast cancer cells’
intrinsic IGFBP3 overexpression in modulation of the brain parenchyma.
It is known that breast cancer patients differentially express IGF-1 and IGFBP3
in the circulation, but the relevance of their expression levels and their contribution
to metastasis is still unknown.

Therefore, the effect of circulating IGF-1 and

IGFBP3 levels on the outcome of brain metastases of IGF-IR-positive breast
cancers should be a subject for future studies.
We show that PPP successfully induced G2/M cell cycle arrest in both, 231Br
and BT474 Br3 cells. As a next step, in vivo studies should examine the efficacy of
PPP in preventing or reducing brain metastases at different doses, in order to
establish whether inhibition of IGF-IR would be a good target to pursue in further
pre-clinical studies.
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CHAPTER 6
APPENDIX:
NUCLEAR AKT IN BRAIN SEEKING
BREAST CANCER CELLS
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6.1 Nuclear AKT signaling
Activated AKT has been previously shown to localize in the nucleus of cancer
cells and correlates with poor progression in several cancers. In myocardial cells,
for example, targeting of AKT to the nucleus resulted in enhanced cell survival and
increased kinase activity (Shiraishi et al., 2004). Furthermore, myocardial epithelial
cells that overexpress IGF-IR have an enrichment of nuclear phospho-AKT Ser47,
which is also associated with enhanced cell survival (Camper-Kirby et al., 2001).
We previously observed that AKT signaling is stimulated by IGF-IR signaling in
our model system (Figures 7 and 12). When we looked at the subcellular activation
profile of AKT, we were surprised to find that AKT was constitutively phosphorylated
in the nucleus of 231Br cells (Figure 26).

Importantly, nuclear phospho-AKT

observed most likely has active kinase function, since we also detected enhanced
endogenous phosphorylation of AKT nuclear substrates, compared to 231 parental
cells which did not express nuclear phospho-AKT (Figure 26). Furthermore, AKT
phosphorylation was further enhanced by stimulation with IGF-1 ligand, which
suggests that constitutive IGF-IR signaling may be at least partially responsible for
enhanced nuclear AKT signaling.
In order to test the hypothesis that IGF-IR increases nuclear AKT signaling, we
obtained nuclear lysates from the 231Br-Vector, 231Br-shIGF-IR (B) and 231BrshIGF-IR (F) cell lines.

231Br Vector cells had Ser473 and Thr307 AKT

phosphorylation, as expected. Ser473 phosphorylation was unaffected by IGF-IR
knockdown in the shIGFR cells, however, AKT phosphorylation at Thr308 was
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downregulated.

The phosphorylation of nuclear AKT ser/thr substrates at the

RXXS/T motif was also partially downregulated in the IGF-IR knockdown cell lines,
although not dramatically, perhaps due to the residual Ser473 phosphorylation.
Next, we were interested in discerning which of the three AKT isoforms is
phosphorylated in the nucleus of 231Br cells. We transiently transfected 231Br cells
with control siRNA, or siRNAs targeting a combination of two or three AKT isoforms.
We then isolated nuclear lysates from siRNA-transfected cells, and assessed the
resulting AKT phosphorylation. AKT1 and AKT3 knockdown contributed the most
significant decrease in phospho-AKT at both Ser473 and Thr308.

This is an

important result since both AKT1 and AKT3, have been implicated in metastasis
and/or in vitro metastatic properties. In thyroid cancer, for example, it was shown
that AKT1 and activated AKT co-localize in the nucleus of malignant cells, but not
normal thyroid cells, and correlates with increased malignancy and migration
(Vasko et al., 2004). Interestingly, it was also shown that an AKT1 mutant lacking a
nuclear export sequence is sufficient to cause increased in vitro migration of Akt1 -/fibroblasts (Saji et al., 2005).

Akt3 deregulation was found to correlate with

melanoma malignancy, and AKT3 expression progressively increases in more
advanced stages of metastasis (Stahl et al., 2004).

Taken together, our data

suggest that IGF-IR signaling axis activation in brain-seeking breast cancer cells
may lead to an enrichment of phosphorylated and kinase-active nuclear AKT,
primarily AKT1 and AKT3, which then may activate nuclear substrates that promote
migration and metastasis. Further studies should validate specific targets enhanced
by this signaling axis, and further clarify the functional significance of nuclear AKT in
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vivo.
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Figure 27
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Figure 27. Nuclear localization of phospho-AKT and enhanced AKT nuclear
substrate activation in brain-seeking breast cancer cells

Lysates of cytosolic and nuclear compartments of 231 and 231Br cells were
obtained. Cytosolic fraction on the left is confirmed by Tubulin expression, and
purity of the nuclear fraction on the right is confirmed by Lamin-B expression.
Nuclear phospho-AKT is found in 231Br cells, but not parental cells. Constitutive
AKT kinase activation is confirmed by serine/threonine phosphorylation of AKT
substrates on the RXXS/T motif. Nuclear AKT and nuclear AKT substrate Ser/Thr
phosphorylation are further stimulated by IGF-1 ligand.
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Figure 28
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Figure 28. Nuclear phospho-AKT and nuclear substrate activation are
downregulated in IGF-IR knockdown brain-seeking breast cancer cells

Lysates of cytosolic and nuclear compartments of 231Br-Vector, 231Br-shIGF-IR
(B) and 231Br-shIGF-IR (F) were obtained. Nuclear AKT phosphorylation at Ser473
is found in 231Br Vector cells and unaffected by IGF-IR knockdown.

AKT

phosphorylation at Thr308 is downregulated in IGF-IR knockdown cells.
Phosphorylation of nuclear AKT serine/threonine substrates on the RXXS/T motif is
partially downregulated in the IGF-IR knockdown cell lines.
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Figure 29
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Figure 29. Nuclear phospho-AKT signal observed is primarily from AKT1 and
AKT3 isoforms.

231Br cells were transiently transfected with control siRNA, or siRNAs targeting a
combination of two or three AKT isoforms. Nuclear lysates from siRNA-transfected
cells were isolated, and AKT phosphorylation was assessed.

AKT1 and AKT3

knockdown contributed the most significant decrease in phospho-AKT at both
Ser473 and Thr308.
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